

**THIS IS
HOW WE
GET TO
SOMEDAY**


YOU GIVE. WE ACT. LIVES SAVED. IN ESSENCE, THIS IS HOW WE GET TO SOMEDAY—THE DAY WHEN CANCER IS NO LONGER PART OF OUR LIVES. AND WE'RE WELL ON OUR WAY. THE LEUKEMIA & LYMPHOMA SOCIETY (LLS) HAS INVESTED MORE THAN \$1 BILLION TO ACCELERATE INNOVATIVE, LIFE-SAVING TREATMENTS THAT ONCE WERE BEYOND OUR IMAGINATION. OUR CURES AND ACCESS AGENDA IMPACTS THE CANCER LANDSCAPE. THE END IS CLOSER WHEN ALL OF US CONCENTRATE OUR FUNDS AND EFFORTS THROUGH LLS. SOMEDAY BECOMES TODAY WHEN WE EACH DECLARE: CANCER ENDS WITH ME.

THE HARRY T. MANGURIAN, JR. FOUNDATION GAVE \$4MM TO SUPPORT LLS'S BEAT AML INITIATIVE.

LLS COMMITTED \$79.8MM TO RESEARCH IN FISCAL YEAR 2014.

THE U.S. FOOD & DRUG ADMINISTRATION APPROVED THE FIRST **BREAKTHROUGH THERAPY**-DESIGNATED TREATMENTS FOR BLOOD CANCER PATIENTS.





LLS LAUNCHED BEAT AML, A COLLABORATION WITH OREGON HEALTH & SCIENCE UNIVERSITY TO IDENTIFY GENES THAT CAUSE AML, AND WORK WITH BIOPHARMACEUTICAL COMPANIES TO TEST NEW AGENTS THAT TARGET THOSE GENES ALONE OR IN COMBINATION TO **PERSONALIZE THERAPY** FOR PATIENTS.



“MY NAME IS RHETT, AND **CANCER ENDS WITH ME!** CANCER CELLS ARE THE BAD GUYS. FOR THREE AND A HALF YEARS, I TOOK CHEMO TO GET THE BAD GUYS OUT.”
RHETT KRAWITT, SURVIVOR.

LLS SUPPORTED **350+** BLOOD CANCER RESEARCH PROJECTS WORLDWIDE.

THE #1 NATIONAL CORPORATE PARTNER FOR LIGHT THE NIGHT, **BURLINGTON** RAISED **\$3MM+**.



MORE THAN **1.1 MILLION** PEOPLE IN THE U.S. ARE **LIVING** WITH, OR ARE IN REMISSION FROM, A BLOOD CANCER.



LLS ANNOUNCED 14 **QUEST FOR CURES** RESEARCH GRANTS TO PROVIDE FUNDING FOR UNMET MEDICAL NEED, AND TO IDENTIFY WHY SOME TREATMENTS ARE NOT SUCCESSFUL FOR CERTAIN PATIENTS.

MAN & WOMAN OF THE YEAR—**RECORD-BREAKING \$30.8MM** RAISED; \$8MM MORE THAN PREVIOUS YEAR.



LLS ANNOUNCED FOUR **SCREEN TO LEAD** GRANTS TO HELP RESEARCHERS DEVELOP NOVEL SMALL MOLECULES THAT TARGET GENES WHICH CAUSE CANCER.

IN 1964, THE FIVE-YEAR SURVIVAL RATE FOR THE MOST COMMONLY DIAGNOSED LEUKEMIA AMONG CHILDREN WAS 3%. **TODAY IT'S 90%.**



PRESIDENT AND CHAIRMAN'S MESSAGE.

With more than 1.1 million people in the U.S. living with or in remission from a blood cancer, the work of The Leukemia & Lymphoma Society (LLS) has never been more important.

We talk about someday being today. These are not just words. LLS has helped advance innovative therapies, initiated unique research collaborations, provided life-saving programs to help patients and caregivers, and advocated at the state and federal levels to ensure access to quality and affordable care. These efforts have helped bring someday home for many blood cancer patients; they would face even greater treatment and quality of life challenges were it not for the work of LLS.

Fiscal year 2014, our 65th anniversary, proved to be a challenging year of adapting and evolving, but also one of reaching meaningful milestones. This year, LLS surpassed \$1 billion of cumulative investments in cancer therapies and saving lives. Innovation requires sustained support from our donors, and their ongoing commitments have been amazing. LLS's decade-long collaboration with Nike for our Team In Training program helped us surpass the \$143 million mark. Our long-time corporate partner, Burlington, raised more than \$3 million through their annual campaign.

LLS has been at the heart of many important advances for blood cancer patients during 2014—from new targeted treatments like ibrutinib, to exciting progress in T-cell immunotherapy, to closing the gap between discovery and drug development through four new partnerships in our Therapy Acceleration Program®.


Other successes come from LLS's advocacy and policy efforts, which are committed to ensuring sustainable access to the best available treatments for all blood cancer patients. Eliminating waiting periods for bone marrow transplants in Oregon and Washington, and establishing parity between insurance coverage for oral and intravenous therapies in Missouri, Maryland, Wisconsin and Arizona, are examples of how LLS's advocacy initiatives help save lives today.

Also in 2014, our executive leadership changed. In February, LLS CEO John Walter stepped down following nearly 20 years of service. John helped guide the expansion of LLS's efforts to accelerate new treatments for blood cancers, as well as our Co-Pay Assistance Program, which has provided almost \$200 million to help patients afford their insurance premiums and drug co-pays. The Board thanked John for his many years of dedication to our mission. Lou DeGennaro accepted the Board's request that he follow John as President and CEO, and Lou leveraged his nine previous years with LLS to hit the ground running.

During this past year, we continued building on the success of the powerful LLS brand platform Someday is Today.™ This simple message calls to mind our contributions to impactful advances, and differentiates us in an ever more competitive fundraising environment. As you'll see in the following pages, your contributions to LLS have immediate and lasting power. You give—we act—lives saved. It's a formula for action that couldn't be any simpler—or more meaningful.



Louis J. DeGennaro, PhD
President & CEO



Timothy S. Durst, JD
Chairman of the Board



AWARDED SIX \$100,000 **NEW IDEA AWARDS**—A PROGRAM SUPPORTING HIGHLY NOVEL RESEARCH CONCEPTS.



MANY OF THE NEW GENERATION OF CANCER PATIENTS MANAGE THEIR CONDITION WITH JUST **A DAILY PILL**.



TEAM IN TRAINING HAS RAISED MORE THAN **\$1.4 BILLION** TO DATE TO HELP FUND OUR MISSION.

LLS HELPED **PASS 12 STATE BILLS** IN 2014 THAT LIMIT PATIENT COST-SHARING ON SPECIALTY DRUGS, IMPROVE COVERAGE FOR TERMINALLY ILL PATIENTS AND ENSURE TIMELY ACCESS TO TREATMENT.

FROM HERE TO SOMEDAY: HOW OUR MISSION IS SHORTENING THE DISTANCE.

Partnering for Cures—Therapy Acceleration and the Targets, Leads and Candidates programs.

At the annual Partnering for Cures in New York City, more than 1,000 leaders in medical research came together, driven by a sense of urgency on getting treatments to patients. LLS was there as a leader in venture philanthropy.

Through our Therapy Acceleration Program, we are bridging the gap between discovery and drug development, creating partnerships with universities and biotechnology and pharmaceutical companies to speed the process.

Louis J. DeGennaro, PhD, LLS president & CEO, participated in 30 meetings with other leaders and highlighted our Targets, Leads and Candidates program, through which we partner with the biopharmaceutical industry to fund early-stage research.

T-cell immunotherapy.

LLS-funded research showed remarkable data on chimeric antigen receptor T-cell immunotherapy—CART immunotherapy—at the 55th American Society of Hematology (ASH) Annual Meeting. Among adults and children with advanced blood cancers, 89% of the acute lymphoblastic leukemia (ALL) patients had a complete response rate and 47% of adult chronic lymphocytic leukemia (CLL) patients responded to the therapy, the first successful and sustained use of genetically engineered T cells to fight leukemia.

LLS grant recipient and CART immunotherapy team leader Carl H. June, MD, of the University of Pennsylvania, explained: “Our findings show that the human immune system and these modified ‘hunter’ cells work together to attack tumors in an entirely new way.” Lee Greenberger, PhD, LLS chief scientific officer, added, “These findings show real promise in the quest to activate and direct the immune system to kill cancer cells.”

Over the past 16 years, LLS has committed \$21 million to this work through 2017.

Additional funds are being directed to agents that take the brakes off the immune system, the so-called immunosystem inhibitors, vaccines to activate the immune system, as well as new CART therapies where the T cells are directed to other blood cancers, including acute myeloid leukemia (AML).

Ibrutinib study results.

Ibrutinib, a targeted oral therapy approved by the FDA to treat patients with relapsed CLL, made news at the 2014 American Society for Clinical Oncology meeting in Chicago.

John Byrd, MD, of The Ohio State University, and a long-time recipient of LLS funding, presented data from a Phase 3 study that showed ibrutinib significantly outperformed ofatumumab. At six months, 83 percent of patients treated with ibrutinib experienced progression-free survival compared to 49 percent of patients on ofatumumab.



TODAY'S CANCER PATIENTS AREN'T JUST SURVIVING, THEY'RE LIVING.

LLS COMMITTED \$7.5MM IN DIRECT RESEARCH FUNDING TO **PEDIATRIC CANCER, 9 PERCENT OF OUR TOTAL RESEARCH COMMITMENT.**

LLS ADVOCATED FOR THE **GABRIELLA MILLER KIDS FIRST RESEARCH ACT, WHICH DEDICATES \$120MM OF FEDERAL FUNDING TO PEDIATRIC RESEARCH AND SIGNED INTO LAW BY PRESIDENT OBAMA IN APRIL.**



LIGHT THE NIGHT WALK RAISED \$58.2MM.



Earlier, Dr. Byrd and colleagues published a study in *The New England Journal of Medicine* identifying mechanisms that cause resistance to ibrutinib, raising hope that understanding these mutations could lead to drug combinations that prevent or treat ibrutinib-resistant CLL.

Beat AML initiative begins.

AML is the most common type of acute leukemia among adults, with less than one-third of newly diagnosed patients in the U.S. surviving beyond five years. LLS kicked off its “Harry T. Mangurian, Jr. Beat AML” fundraising initiative in New York City, featuring Brian Druker, MD, Director, Oregon Health & Science University Knight Cancer Institute (OHSU), and lead investigator of LLS’s groundbreaking collaboration with OHSU.

With treatment options for AML largely unchanged in 30 years, Dr. Druker spoke about creating a network of collaborators open to testing new ideas, including drug combinations.

Dr. DeGennaro emphasized bringing together researchers and the U.S. Food and Drug Administration (FDA). “From 2000 through 2013, nearly 40 percent of the new anti-cancer treatments approved by the FDA were first approved for blood cancer patients. That’s more first approvals than for any other group of cancer patients,” he noted.

ASH Annual Meeting.

At the 55th American Society of Hematology (ASH) Annual Meeting and Exposition, researchers from around the world shared the latest findings on targeted therapies,

immunotherapies and epigenetics. Topics included the recently approved obinutuzumab, an antibody that helps kill blood cancer cells that express a protein found in many B cell lymphomas.

“LLS funds research from early clinical work to clinical trials, and even partners with industry, to accelerate therapies through the drug discovery pipeline,” said Dr. Greenberger. “Our investments have helped advance therapies that are saving lives today.”

Also, LLS hosted a satellite symposium on how cancer genomics and technology combine to advance new therapies for treatment of blood cancer patients.

Translational Research Program (TRP) 20th anniversary.

Our Translational Research Program, designed to advance promising discoveries from lab to clinic, celebrates 20 years of helping to advance the work of some of the most renowned blood cancer researchers, including Brian Druker, MD, of Oregon Health & Science University, Carl June, MD, of the University of Pennsylvania, and John Byrd, MD, of The Ohio State University.

LLS is proud of supporting the work of Dr. Druker. His breakthrough studies of the targeted oral therapy, imatinib (Gleevec®), and later clinical trials led to the accelerated FDA approval of the drug that is now saving lives of patients with chronic myeloid leukemia (CML), and helping patients with other cancers as well. A video about Dr. Druker can be viewed on our YouTube Channel.

FOR LLS, THE **UFCW** RAISED \$2.6MM IN CANADA AND \$1.9MM IN THE U.S.



LLS HELPED **ACHIEVE ORAL PARITY** LEGISLATION IN 6 STATES; CURRENT TOTAL IS 33 STATES PLUS D.C.

LLS SUPPORTED **\$15MM** IN SPECIALIZED CENTER OF RESEARCH GRANTS.



IN 65 YEARS OF INVESTING IN CANCER THERAPIES AND SAVING LIVES, LLS **SURPASSED THE \$1B** MILESTONE.



State policy: Eliminating waiting periods for transplants in Oregon and Washington.

LLS mobilized advocacy efforts to successfully reverse a 24-month waiting period for previously uninsured bone marrow transplant patients in the Oregon health insurance marketplace. LLS's access team brought this issue to the attention of the public and state health policy officials to help remove this barrier to a critical therapy for the patients who urgently need it.

Similar action also reversed a 3-month waiting period in Washington state. These are important examples of how LLS's advocacy initiatives work to save lives every day.

New Oral parity laws became reality in 4 states.

LLS advocacy helped make oral parity a reality in Missouri, Maryland, Wisconsin and Arizona. Oral parity requires insurance plans to charge consistent co-payments, deductibles, or coinsurance amounts for anticancer medications, regardless of whether the therapy is self-administered or administered intravenously or by injection.

Equitable access to oral therapies allows blood cancer patients and their doctors to decide the most clinically appropriate treatment and keeps patients from having to choose whether or not they can afford to fill their prescription.

The LLS government affairs team, along with our advocates, directly contributed to the passage of oral parity bills in five states in the last two years and a total of ten oral parity bills.

LLS patient support for the Affordable Care Act (ACA).

LLS played an active role in informing the public about the effect the ACA could have on blood cancer patients and the types of questions to ask their insurance companies. ACA bans lifetime limits on care, and allows dependents to stay on their parent's health insurance up to age 26. Consumers with pre-existing conditions such as a blood cancer cannot be denied coverage based on their health status.

While there are many beneficial aspects of the law, there are also issues that blood cancer patients need to be aware of, such as narrow networks and high cost-sharing, which can prevent patients from getting access to the care they need.

LLS's Information Resource Center (IRC), as well as local patient support staff, helped patients understand their options and eligibility for insurance subsidies when signing up for coverage through the new federal and state marketplaces.

The Affordable Care Act: Milliman report raises concerns for blood cancer patients.

LLS continues to be a resource for our patients. As part of LLS's efforts to help educate patients about the Affordable Care Act, we commissioned the Milliman Report on Healthcare Exchanges in Seven States. It provided a look at the 2014 individual benefit designs, coverage benefits and premiums for policies sold on seven state health insurance exchanges—California, New York, Florida, Texas, New Jersey, Michigan and Washington. Narrow networks and high cost-sharing were among the concerns raised.



INFORMATION RESOURCE CENTER (IRC) SPECIALISTS FIELDED **62,000+ INQUIRIES**; TOUCHING MORE THAN **1MM PATIENTS** SINCE ITS INCEPTION IN 1987.

IRC SPECIALISTS PERFORMED **6,000 CLINICAL TRIAL** SEARCHES USING LLS'S TRIALCHECK TOOL.

LLS **EXPANDED IRC HOURS** TO 9 A.M. – 9 P.M. EASTERN TIME.

LLS PARTICIPANTS IN THE **NIKE WOMEN'S MARATHON SAN FRANCISCO** RAISED **\$9MM**; NIKE WOMEN'S HALF MARATHON IN D.C., **\$4.7MM**.



LLS-FUNDED RESEARCHERS REPORTED THAT 27 OF 30 ACUTE LYMPHOBLASTIC LEUKEMIA PATIENTS TREATED WITH CTL-019 EXPERIENCED **COMPLETE REMISSION**.



Federal policy: Kids First Research Act.

The Gabriella Miller Kids First Research Act increases much needed funding for pediatric medical research activities administered through the Common Fund of the National Institutes of Health.

This law expands pediatric research activities into cancer, autism and other diseases impacting children.

The law was passed by both the House of Representatives and the Senate, then signed into law by President Obama. LLS played a key role in advocating on behalf of this important piece of legislation.

LLS Co-Pay Assistance Program milestone.

LLS has raised more than \$200 million for our Co-Pay Assistance Program since its inception in 2007.

The program provides support for prescription drug co-pays and health insurance premiums for blood cancer patients who meet certain income requirements. Patients with private insurance, Medicare beneficiaries under Medicare Part B and/or Plan D, Medicare Supplementary Health Insurance and Medicare Advantage are eligible.

Through our Co-Pay Assistance Program, LLS has made blood cancer treatments available and affordable for more than 36,000 patients to date.

IRC expands patient service.

LLS has expanded hours for its Information Resource Center (IRC), a toll-free call center staffed with master's level healthcare professionals knowledgeable on the latest information on all blood cancers.

The call center can immediately assist callers in English, Spanish and French, with translations available in more than 140 languages.

LLS's IRC stands out among health organization call centers because of the depth of individualized attention offered. Since its inception in 1987, the IRC has helped more than one million callers.

Increasing service hours is part of our strategic plan to expand mission offerings. We provide support services to patients and families, ensuring patients have access to quality, affordable care.


LLS FORMED COLLABORATIONS WITH FOUR **NEW TAP PARTNERS**—INCLUDING ARGENX, STEMLINE, AFFIMED AND STANFORD UNIVERSITY—25 ACTIVE PROGRAMS IN TOTAL.

SINCE THE EARLY 1960S, FIVE-YEAR **SURVIVAL RATES** FOR MANY BLOOD CANCER PATIENTS HAVE DOUBLED, TRIPLED OR EVEN QUADRUPLED.



SCHOOL & YOUTH RAISED \$27.3MM.

LLS **COMMITTED \$23MM** IN TRANSLATIONAL RESEARCH PROGRAM GRANTS, ADDRESSING AREAS OF UNMET MEDICAL NEED, AND HELPING ADVANCE PROJECTS FROM LAB TO CLINIC.



HOW WE'RE GETTING EVERYONE INVOLVED IN OUR MISSION.

Donor Development—Mission Critical.

Donor Development also experienced a record-setting year for LLS, raising \$29.2 million. The year was highlighted by the launching of the \$8.3 million Beat AML fundraising campaign. To date, \$6.5 million has been pledged, spearheaded by the Harry T. Mangurian, Jr. Foundation's lead gift of \$4 million. Long-time LLS volunteer Michael Copley is serving as the National Chair of the three-year campaign motivated by the loss of his young daughter who passed from AML two decades ago.

Major Gifts, donations of \$10,000 or more, directly funded countless other mission critical programs ranging from new research in our scientific pediatric portfolio to greater outreach through our Transportation Assistance Fund. An additional \$5.3 million was realized via bequests, a true lasting legacy to LLS's mission and our quest for cures and access for all touched by blood cancers.

***Scientific American Worldview* editorial.**

A *Scientific American Worldview* editorial written by Dr. DeGennaro focuses on how nonprofits can be catalysts for collaboration to advance new therapies and cures.

By enabling drug discovery from beginning to end—identifying urgent unmet medical needs, creating partnerships with biopharmaceutical companies and academic research,

and with a milestone-driven agenda to manage product development projects—DeGennaro illustrates how the process can be accelerated.

The article addresses specific challenges faced in treating acute myeloid leukemia and details how LLS joined with Brian Druker, MD, Oregon Health & Science University, to make precision medicine a reality.



IN JUNE, THE **LEUKEMIA CUP REGATTA** PASSED \$50MM SUPPORT SINCE THE FIRST EVENT IN 1987.

ON MISSION DAY IN MAY, **375 ADVOCATES** ATTENDED **329 MEETINGS** ON CAPITOL HILL. WE COLLECTED **16,589 SIGNATURES** DEMANDING ELECTED OFFICIALS EXPAND ACCESS TO TREATMENT FOR CANCER PATIENTS AND THEIR FAMILIES.



THE FIRST **ORAL THERAPY** TARGETING B-CELL CANCERS WAS FDA-APPROVED FOR PATIENTS WITH RELAPSED CLL AND MANTLE CELL LYMPHOMA.



THE SURVIVAL RATE FOR MYELOMA MORE THAN **TRIPLED** SINCE THE 1960s.

BREAKTHROUGH FUNDRAISING AND THE SUCCESS OF OUR MISSION.

LLS: Leading the way to a world without blood cancers.

For 65 years, LLS has been helping to lead the way to a world without blood cancers. This year, LLS surpassed a momentous milestone: We have invested more than \$1 billion in research to promote our cause, find cures and achieve a world without blood cancers.

At a three-day conference in Washington, D.C., all aspects of our cures and access agenda were discussed. Our advocacy enables us to impact the public policy discussion on federal legislative and regulatory issues that affect patient access.

On the steps of Capitol Hill, as one of 375 advocates, Ethan Zohn, star of “Survivor: Africa,” and a two-time Hodgkin lymphoma survivor, implored, “What’s the point of research if patients don’t have access to the therapies?”

Charles Esten, an actor/musician who plays Deacon Claybourne on the TV show “Nashville”, performed for the excited crowd. Esten has supported LLS since his young daughter, now a survivor, was diagnosed with leukemia.

Jessica Melore, a motivational speaker and dedicated LLS volunteer, suffered a heart attack at age 16, endured a heart transplant, a leg amputation and is a two-time lymphoma survivor now six years in remission. She spoke of the urgency of the LLS mission: “LLS isn’t satisfied with finding a cure 50 years from now. Someday is today.”

A giant “Declare It!” wall engaged attendees in our movement, declaring “Cancer Ends with Me.”

Burlington Stores and Light The Night.

For the 12th consecutive year, Burlington Stores, with its more than 520 locations nationwide, joined the LLS Light The Night® Walk campaign to raise funds to help find cures and ensure access to treatments for patients with blood cancer. The national off-price retailer encouraged its customers to make a donation at check-out and enrolled 28,000 associates to participate in Light The Night Walks all across the country.

Over a 17-week campaign, Burlington, LLS’s number one national corporate partner, raised more than \$3 million, bringing the total raised over the many years of partnership to more than \$19 million. “By engaging our generous customers and associates, our partnership with LLS and The Light The Night Walk enables us to help fund life-saving cancer research and treatments in a meaningful way,” said Tom Kingsbury, President and CEO of Burlington Stores.



LLS ADVOCATED TO **ELIMINATE** OREGON'S 2-YEAR WAITING PERIOD FOR STEM CELL TRANSPLANTS FOR PREVIOUSLY UNINSURED BLOOD CANCER PATIENTS.

THE **PATTI ROBINSON FIRST CONNECTION PROGRAM**, A FREE LLS SERVICE, MATCHED 4,518 PATIENTS AND LOVED ONES WITH A TRAINED VOLUNTEER WHO HAS SHARED A SIMILAR EXPERIENCE.

MOMS IN TRAINING, A NEW EXTENSION OF TEAM IN TRAINING, ENLISTED 1,000 MOMS IN 36 CHAPTERS TO RAISE ALMOST \$1MM.



LLS PROVIDED **\$49.2MM** IN **CO-PAY SUPPORT** TO BLOOD CANCER PATIENTS.



Nike and 10 years of saving lives.

The Nike Women's Marathon San Francisco celebrates women coming together through the shared passion of taking on a physical endurance challenge while also taking aim at cancer.

October 2013 marked the 10th annual Nike Women's Marathon San Francisco. Among 30,000 participants from around the world were 2,900 members of LLS's Team In Training, who raised more than \$9 million to help LLS find cures for blood cancers and ensure access to treatments for patients.

UFCW supports LLS.

The United Food and Commercial Workers (UFCW), the union representing grocery and other retail workers, has been a dedicated LLS partner since 1983. The union has raised more than \$60 million to help LLS advance its mission over that time. Its 1.3 million union members are truly helping blood cancer patients live better, longer lives.

In fiscal year 2014 alone, the union generated more than \$2.6 million in Canada and \$1.9 million for LLS in the U.S. Significant in its fundraising effort in Canada is the annual "Returns For Leukemia" bottle drive, organized by UFCW Local 12R24 and The Beer Store. This Ontario campaign converts deposits on bottles into donations. Canadian members also participate in other fundraising events, including golf tournaments, dinners, auctions and LLS campaigns such as Light The Night Walk. In the U.S., the fundraising involves a variety of events, including golf

tournaments, dinners and auctions, and participation in LLS campaigns.

Man & Woman of the Year record-breaking year.

For their support of LLS's mission, two leading fundraisers were named the 2014 National Man & Woman of the Year, the 24th annual awards for this prestigious program. The record-breaking campaign total of \$30.8 million is nearly \$8 million more than was raised last year.

Dr. Christos Giannoulis of Chicago and Samara Wolpe of Los Angeles earned this coveted title. These two "Champions of Hope" were among 900 candidates from across the country to vie for the award.

The new All Star Alumni campaign was launched to give Man & Woman of the Year alumni the opportunity to use their talents, contacts and creativity to represent their local campaign on a larger platform. Six returning competitors raised \$484,940 to support LLS's work. The two national All Star winners were Kim Tindall and Ryan LaFontaine. The new initiative also highlighted the fact that LLS's job is not done until all blood cancer patients have cures and access to the treatments they need.

RESEARCH GRANTS

THE MARSHALL A. LIGHTMAN SPECIALIZED CENTER OF RESEARCH

The Specialized Center of Research Program funds multi-disciplinary research by teams of leading-edge academic investigators that hasten the discovery and development of better treatments for leukemia, lymphoma and myeloma patients. A center is composed of at least three independent research programs that are integrated and supported by scientific core laboratories.

Jerry Adams, PhD 2013
Walter & Eliza Hall Institute of
Medical Research

Frederick Alt, PhD 2012
Boston Children's Hospital

Jon Aster, MD 2013
Brigham & Women's Hospital

John Byrd, MD 2011¹
The Ohio State University

William Carroll, MD 2014
New York University
School of Medicine

Brian Druker, MD 2011
Oregon Health & Science
University

Irene Ghobrial, MD 2014²
Dana-Farber Cancer Institute

Anthony Green, MD, PhD 2012
University of Cambridge

Helen Heslop, MD 2014
Baylor College of Medicine

Carl June, MD 2013³
University of Pennsylvania

Thomas Kipps, MD, PhD 2014
University of California, San Diego

Jonathan Licht, MD 2013
Northwestern University
School of Medicine

CAREER DEVELOPMENT PROGRAM (SCHOLARS AND CLINICAL SCHOLARS)

The Career Development Program provides stipends to investigators of exceptional promise in the early stages of their careers, helping them devote their careers to research in leukemia, lymphoma or myeloma.

Gregory Abel, MD 2013
Dana-Farber Cancer Institute

K Mark Ansel, PhD 2013
University of California,
San Francisco

Scott Armstrong, MD, PhD 2010⁴
Children's Hospital Boston

Craig Bassing, PhD 2011
The Children's Hospital of
Philadelphia

Julie Blander, PhD 2015*
Mount Sinai School of Medicine

Jennifer Brown, MD, PhD 2011
Dana-Farber Cancer Institute

Patrick Brown, MD 2012⁵
Johns Hopkins University
School of Medicine

Claudio Brunstein, MD, PhD 2011
University of Minnesota—
Twin Cities

Jan Burger, MD, PhD 2014
The University of Texas
MD Anderson Cancer Center

George Calin, MD 2012
The University of Texas
MD Anderson Cancer Center

Iain Cheeseman, PhD 2013
Whitehead Institute for
Biomedical Research

Jing Chen, PhD 2011
Emory University

Yuh Min Chook, PhD 2011
The University of Texas
Southwestern Medical Center

Dipanjan Chowdhury, PhD 2015*
Dana-Farber Cancer Institute

Christopher Cogle, MD 2013
University of Florida

Yali Dou, PhD 2013
University of Michigan

Mary Eapen, MD 2010⁶
Medical College of Wisconsin

Benjamin Ebert, MD, PhD 2013
Brigham & Women's Hospital

Thomas Fazio, PhD 2015*
University of Massachusetts
Medical School

Elsa Flores, PhD 2012
The University of Texas
MD Anderson Cancer Center

Maxim Frolov, PhD 2011
University of Illinois - Chicago

Andrei Goga, MD, PhD 2013
University of California,
San Francisco

Ananda Goldrath, PhD 2012
University of California, San Diego

Jolanta Grembecka, PhD 2014
University of Michigan

Jonathan Higgins, PhD 2012
Brigham & Women's Hospital

Morgan Huse, PhD 2015*
Memorial Sloan Kettering
Cancer Center

Holbrook Kohrt, MD, PhD 2015*
The Board of Trustees of the
Leland Stanford Junior University

Marina Konopleva, MD, PhD 2012
The University of Texas
MD Anderson Cancer Center

John Koreth, MD, PhD 2014
Dana-Farber Cancer Institute

Ross Levine, MD 2013
Memorial Sloan Kettering
Cancer Center

Ming Li, PhD 2015*
Memorial Sloan Kettering
Cancer Center

Ivan Maillard, MD, PhD 2014
University of Michigan

Sami Malek, MD 2012
University of Michigan

William Matsui, MD 2010⁷
Johns Hopkins University
School of Medicine

Hanna Mikkola, MD, PhD 2012
University of California,
Los Angeles

Golam Mohi, PhD 2014
SUNY Upstate Medical Center

James Mulloy, PhD 2011⁸
Childrens Hospital Medical
Center-Cincinnati

Markus Muschen, MD 2011⁹
University of California,
San Francisco

Ryoma Ohi, PhD 2014
Vanderbilt University
Medical Center

Sophie Paczesny, MD, PhD 2015*
Indiana University

Emmanuelle Passegué, PhD 2013
University of California,
San Francisco

Cathie Pflieger, PhD 2013
Mount Sinai School of Medicine

Joel Pomerantz, PhD 2012
Johns Hopkins University
School of Medicine

Noopur Raje, MD 2010¹⁰
Massachusetts General Hospital

Pavan Reddy, MD 2011
University of Michigan

Boris Reizis, PhD 2011
Columbia University Medical
Center

Loredana Ruggeri, MD, PhD 2011
University of Perugia

Davide Ruggero, PhD 2011
University of California,
San Francisco

Talya Salz, PhD 2014
Memorial Sloan Kettering
Cancer Center

Karsten Sauer, PhD 2011
The Scripps Research Institute

Joseph Scandura, MD, PhD 2014
Weill Medical College of
Cornell University

Tait Shanafelt, MD 2013
Mayo Clinic Rochester

Jane Skok, PhD 2011
New York University
School of Medicine

Merav Socolovsky, MD, PhD 2013
University of Massachusetts
Medical School

Kimberly Stegmaier, MD 2014
Dana-Farber Cancer Institute

Ulrich Steidl, MD, PhD 2015*
Albert Einstein College of Medicine
of Yeshiva University

Enrico Tiacchi, MD 2014
University of Perugia

Raoul Tibes, MD, PhD 2015*
Mayo Clinic Arizona

Wei Tong, PhD 2014
The Children's Hospital
of Philadelphia

David Traver, PhD 2013
University of California, San Diego

Amit Verma, MD 2013
Albert Einstein College of Medicine
of Yeshiva University

Loren Walensky, MD, PhD 2015*
Dana-Farber Cancer Institute

Roland Walter, MD, PhD, MS 2015*
Fred Hutchinson Cancer
Research Center

Matthew Walter, MD 2014
Washington University of St. Louis
School of Medicine

Hengbin Wang, PhD 2013
The University of Alabama at
Birmingham

Wenyi Wei, PhD 2014
Beth Israel Deaconess
Medical Center

David Weinstock, MD 2014
Dana-Farber Cancer Institute

Hans-Guido Wendel, MD 2015*
Memorial Sloan Kettering
Cancer Center

Johnathan Whetstone, PhD 2015*
Massachusetts General Hospital

Catherine Wu, MD 2015*
Dana-Farber Cancer Institute

Xiaochun Yu, MD, PhD 2015*
The Regents of the University of
Michigan

Shan Zha, MD, PhD 2014
Columbia University
Medical Center

¹ Dr. John Byrd is funded in part by Rita Cavanagh & Gerald Kafka, The Jim Jacobs Charitable Foundation, Elaine S. Smith, Phyllis & Douglas A. Smith, and Judy & Michael H. Thomas.

² Dr. Irene Ghobrial is funded in part by the Edward P. Evans Foundation

³ Dr. Carl June is funded in part by the Cora and John H. Davis Foundation, Imagine a Cure for Leukemia and The Orokawa Foundation.

⁴ Dr. Scott Armstrong is fully funded by Baker Botts L.L.P.

⁵ Dr. Patrick Brown is fully funded by The Orokawa Foundation.

⁶ Dr. Mary Eapen is funded in part by The Greater Milwaukee Foundation, Inc.

⁷ Dr. William Matsui is the Millennium: The Takeda Oncology Company Scholar.

⁸ Dr. James Mulloy is funded in part by The Marge & Charles J. Schott Foundation.

⁹ Dr. Markus Muschen is funded in part by Laurie Burns and two anonymous donors.

¹⁰ Dr. Noopur Raje is the Millennium: The Takeda Oncology Company Scholar.

Chengcheng Zhang, PhD 2014
The University of Texas
Southwestern Medical Center

Jing Zhang, PhD 2014¹¹
University of Wisconsin-Madison

Xiaolan Zhao, PhD 2014
Memorial Sloan Kettering
Cancer Center

Lee Zou, PhD 2012
Massachusetts General Hospital

Elina Zuniga, PhD 2013
University of California, San Diego

**CAREER DEVELOPMENT
PROGRAM (SPECIAL FELLOWS,
CLINICAL SPECIAL FELLOWS,
AND FELLOWS)**

The Career Development Program provides stipends to investigators of exceptional promise in the early stages of their careers, helping them devote their careers to research in leukemia, lymphoma or myeloma.

Alison Adams, PhD 2014
Yale University

Cassandra Adams, PhD 2013
University of California,
San Francisco

Koshi Akahane, MD, PhD 2014
Dana-Farber Cancer Institute

Spencer Alford, PhD 2015*
The Board of Trustees of the Leland
Stanford Junior University

Lukas Baitsch, PhD 2013
Dana-Farber Cancer Institute

Burton Barnett, PhD 2015*
The Regents of the
University of California, San Diego

Cora Bergantinos, PhD 2015*
Columbia University Medical Center

Ami Bhatt, MD, PhD 2014
Dana-Farber Cancer Institute

Kivanc Birsoy, PhD 2014
Whitehead Institute for
Biomedical Research

Jessica Blackburn, PhD 2014
Massachusetts General Hospital

Andres Blanco, PhD 2015*
Children's Hospital Boston

Vincenzo Calvanese, PhD 2014
University of California, Los Angeles

Marcella Cesana, PhD 2015*
Children's Hospital Boston

Tiffany Chang, MD 2014
University of California,
San Francisco

Mo Chen, PhD 2013
The Rockefeller University

Michael Chu, MD 2015*
The Board of Trustees of the
Leland Stanford Junior University

Hauke Cornils, PhD 2013
Dana-Farber Cancer Institute

David DiLillo, PhD 2013
The Rockefeller University

Zhixun Dou, PhD 2015*
University of Pennsylvania

Jonathan Driver, PhD 2014
University of Washington

Cihangir Duy, PhD 2013¹²
Weill Medical College of
Cornell University

Chen Fang, PhD 2014¹³
Fred Hutchinson Cancer
Research Center

Eva Fast, PhD 2015*
President & Fellows of
Harvard College

Xiaofei Gao, PhD 2014
Whitehead Institute for
Biomedical Research

¹³ Dr. Chen Fang is funded in part by The Kent Joshi and the Melryder Foundation.

¹⁴ Dr. Elisa Oricchio is fully funded by the Gertrude B. Elion Endowment Fund.

Jacqueline Garcia, MD 2015*
The Board of Trustees of the
Leland Stanford Junior University

Karen Gascoigne, PhD 2013
Whitehead Institute for
Biomedical Research

Charles Gawad, MD 2014
The Board of Trustees of the
Leland Stanford Junior University

Luke Gilbert, PhD 2014
University of California,
San Francisco

Stephanie Grainger, PhD 2015*
University of California, San Diego

Michael Green, PhD 2013
The Board of Trustees of the
Leland Stanford Junior University

Sarah Hainer, PhD 2014
University of Massachusetts
Medical School

Daniel Herranz, PhD 2013
Columbia University Medical Center

Kuo-Chiang Hsia, PhD 2013
The Rockefeller University

Alexandre Iannello, PhD 2014
University of California, Berkeley

Caron Jacobson, MD 2014
Dana-Farber Cancer Institute

Ana Janic, PhD 2014
Walter and Eliza Hall
Institute of Medical Research

Jared Johnson, PhD 2013
Beth Israel Deaconess
Medical Center

Stephanie Johnson, PhD 2015*
University of California,
San Francisco

Brian Jonas, MD, PhD 2013
The Board of Trustees of The
Leland Stanford Junior University

Christopher Kanakry, MD 2014
Johns Hopkins University

¹⁵ Dr. Sarwish Rafiq is The Jake Wetchler Foundation Fellow of LLS.

Michael Khodadoust,
MD, PhD 2015*
The Board of Trustees of the
Leland Stanford Junior University

Seoyoung Kim, PhD 2015*
Memorial Sloan Kettering
Cancer Center

Maria Kleppe, PhD 2014
Memorial Sloan Kettering
Cancer Center

Latika Kohli, PhD 2015*
University of California,
San Francisco

Andrew Lane, MD, PhD 2013
Dana-Farber Cancer Institute

Yan Li, PhD 2013
University of Pennsylvania

Kaifeng Lin, PhD 2013
University of North Carolina at
Chapel Hill

Xiangyu Liu, PhD 2014
Columbia University
Medical Center

Camille Lobry, PhD 2013
New York University
School of Medicine

Michael Lofgren, PhD 2015*
Harvard Medical School

Alexis Lomakin, PhD 2013
Harvard Medical School

Marko Lööke, PhD 2015*
Massachusetts
Institute of Technology

Sidinh Luc, PhD 2014
Children's Hospital Boston

Zhuojuan Luo, PhD 2014
Stowers Institute for
Medical Research

Julia Maxson, PhD 2014
Oregon Health &
Science University

Jeffrey McKnight, PhD 2014
Fred Hutchinson
Cancer Research Center

Sarah Mitchell, PhD 2013
University of Colorado at Boulder

Marsilius Mues, PhD 2015*
University of California,
San Francisco

Jagan Muppidi, MD, PhD 2013
University of California,
San Francisco

Thang Nguyen, PhD 2014
California Institute of Technology

Virginie Olive, PhD 2013
University of California, Berkeley

Kyla Omilusik, PhD 2013
University of California, San Diego

Tonis Org, PhD 2013
University of California,
Los Angeles

Elisa Oricchio, PhD 2013¹⁴
Memorial Sloan Kettering
Cancer Center

Johnnie Orozco, MD, PhD 2013
Fred Hutchinson
Cancer Research Center

Ana Ortega Molina, PhD 2014
Memorial Sloan Kettering
Cancer Center

Christopher Ott, PhD 2013
Dana-Farber Cancer Institute

Wen Pan, PhD 2015*
Yale University

Heather Pua, MD, PhD 2014
University of California,
San Francisco

Alexandre Puissant, PhD 2013
Dana-Farber Cancer Institute

Sarwish Rafiq, PhD 2014¹⁵
Memorial Sloan Kettering
Cancer Center

Kaushik Ragunathan, PhD 2014
Harvard Medical School

Parvathi Ranganathan, PhD 2014
The Ohio State University

John Reagan, MD 2014
Rhode Island Hospital

Justin Reitsma, PhD 2015*
California Institute of Technology

Jessica Ridilla, PhD 2015*
Brandeis University

Cory Rillahan, PhD 2015*
Memorial Sloan Kettering
Cancer Center

Kathryn Roberts, PhD 2014
St. Jude Children's Research Hospital

Amir Schajnovitz, PhD 2015*
President & Fellows of
Harvard College

Claudio Scoppo, PhD 2014
Columbia University
Medical Center

Zhen Shen, PhD 2015*
The Rockefeller University

Alan Shih, MD, PhD 2015*
Memorial Sloan Kettering
Cancer Center

Lev Silberstein, MD, PhD 2013
Massachusetts General Hospital

Richelle Sopko, PhD 2013
Harvard Medical School

Jamshid Sorouri Khorashad,
MD, PhD 2015*
University of Utah

Jamie Spangler, PhD 2013
The Board of Trustees of the
Leland Stanford Junior University

Mayumi Sugita, MD 2013
University of Pennsylvania

Kendra Sweet, MD 2014
H. Lee Moffitt Cancer Center &
Research Institute

Benjamin Thompson, PhD 2013
Northwestern University

* Newly awarded or renewed grants in fiscal year 2015

RESEARCH GRANTS (continued)

Shih-Chieh Ti, PhD 2014
The Rockefeller University

Anastasia Tikhonova, PhD 2015*
New York University
School of Medicine

Joanna Tober, PhD 2012¹⁶
University of Pennsylvania

Gianluca Varetto, PhD 2014
Dana-Farber Cancer Institute

Isana Veksler-Lublinsky, PhD 2015*
University of Massachusetts
Medical School

Youzhong Wan, PhD 2013
Dana-Farber Cancer Institute

Lin Wang, PhD 2013
University of California, Berkeley

Matthew Warr, PhD 2013
University of California,
San Francisco

Nathan Westcott, PhD 2014
The Rockefeller University

Jennifer Woyach, MD 2013
The Ohio State University

Mingyi Xie, PhD 2013
Yale University

Xiaodi Yu, PhD 2014
Children's Hospital Boston

Chongzhi Zang, PhD 2013
Dana-Farber Cancer Institute

Joshua Zeidner, MD 2015*
University of North Carolina at
Chapel Hill

Haojian Zhang, PhD 2014
Dana-Farber Cancer Institute

Yu Zhang, PhD 2015*
Children's Hospital Boston

Grace Zheng, PhD 2013
The Board of Trustees of the
Leland Stanford Junior University

Bo Zhou, PhD 2013
The University of Texas
Southwestern Medical Center

TRANSLATIONAL RESEARCH PROGRAM

The Translational Research Program supports outstanding investigations deemed by our expert advisors most likely to translate basic biomedical discoveries into new, safe and effective treatments, ultimately prolonging and enhancing patients' lives.

Gheath Al-Atrash, DO, PhD 2015*
The University of Texas
MD Anderson Cancer Center

Stephen Ansell, MD, PhD 2013¹⁷
Mayo Clinic Rochester

Saro Armenian, DO, MPH 2012¹⁸
Beckman Research Institute
of the City of Hope

Mukta Arora, MD 2014
University of Minnesota

David Avigan, MD 2014
Beth Israel Deaconess
Medical Center

Robert Baiocchi, MD, PhD 2014
The Ohio State University

Leif Bergsagel, MD 2013
Mayo Clinic Arizona

Irwin Bernstein, MD 2013
Fred Hutchinson Cancer
Research Center

Ravi Bhatia, MD 2014
Beckman Research Institute
of the City of Hope

Smita Bhatia, MD, MPH 2013
Beckman Research Institute
of the City of Hope

Bruce Blazar, MD 2015*
University of Minnesota

Katherine Borden, PhD 2014
University of Montreal

Jennifer Brown, MD, PhD 2013
Dana-Farber Cancer Institute

Jose Cancelas, MD, PhD 2013
Cincinnati Children's Hospital
Medical Center

Jennifer Carew, PhD 2013
The University of Texas Health
Science Center at San Antonio

Lucio Castilla, PhD 2015*
University of Massachusetts
Medical School

Leandro Cerchietti, MD 2014
Weill Medical College of
Cornell University

Xiu-bao Chang, PhD 2014
Mayo Clinic Arizona

Jianjun Chen, PhD 2014
The University of Chicago

Selina Chen-Kiang, PhD 2011
Weill Medical College of
Cornell University

Eric Chow, MD 2013
Fred Hutchinson Cancer
Research Center

Tomasz Cierpicki, PhD 2014
University of Michigan

Curt Civin, MD 2014
University of Maryland

James Coghill, MD 2015*
University of North Carolina at
Chapel Hill

Seth Corey, MD 2014
Northwestern University

John Crispino, PhD 2013
Northwestern University

Alan D'Andrea, MD 2013
Dana-Farber Cancer Institute

Chi Dang, MD, PhD 2014
University of Pennsylvania

Bimalangshu Dey, MD, PhD 2014
Massachusetts General Hospital

Alan Eastman, PhD 2013
Dartmouth College

Elizabeth Eklund, MD 2014
Northwestern University

Rudi Fasan, PhD 2014
University of Rochester

Adolfo Ferrando, MD, PhD 2015*
Columbia University
Medical Center

Maria Figueroa, MD 2014
Weill Medical College of
Cornell University

Stephen Forman, MD 2014
Beckman Research Institute
of the City of Hope

Mark Frattini, MD, PhD 2015*
Columbia University
Medical Center

Paul Frenette, MD 2015*
Albert Einstein College of
Medicine of Yeshiva University

Karin Gaensler, MD 2014
University of California,
San Francisco

Patricia Gallagher, PhD 2014
Wake Forest University
Health Sciences

Irene Ghobrial, MD 2013
Dana-Farber Cancer Institute

Steven Grant, MD 2015*
Virginia Commonwealth University

Timothy Graubert, MD 2013
Washington University in St. Louis

James Griffin, MD 2013
Dana-Farber Cancer Institute

H. Leighton Grimes, PhD 2013¹⁹
Cincinnati Children's Hospital
Medical Center

Monica Guzman, PhD 2013
Weill Medical College of
Cornell University

Duane Hassane, PhD 2013
Weill Medical College of
Cornell University

Christoph Heuck, MD 2013
University of Arkansas for
Medical Sciences

Ronald Hoffman, MD 2013
Mount Sinai School of Medicine

Robert Hromas, MD 2013
University of Florida

Javeed Iqbal, PhD 2014
University of Nebraska
Medical Center

Richard Jones, MD 2015*
Johns Hopkins University
School of Medicine

Andrew Kung, MD, PhD 2015*
Columbia University
Medical Center

John Kuruvilla, MD 2013
University Health Network

Dean Lee, MD, PhD 2014
The University of Texas
MD Anderson Cancer Center

Anthony Letai, MD, PhD 2013
Dana-Farber Cancer Institute

Ross Levine, MD 2013
Memorial Sloan Kettering
Cancer Center

Mignon Loh, MD 2015*
University of California,
San Francisco

A. Look, MD 2013
Dana-Farber Cancer Institute

Thomas Loughran, MD 2014²⁰
University of Virginia

Leo Luznik, MD 2013
Johns Hopkins University
School of Medicine

Jaroslav Maciejewski,
MD, PhD 2013
Cleveland Clinic Foundation

Ivan Maillard, MD 2015*
University of Michigan

Tak Mak, PhD 2013
University Health Network

Matthew Matasar, MD 2014²¹
Memorial Sloan Kettering
Cancer Center

Ari Melnick, MD 2014
Weill Medical College of
Cornell University

Rodney Miles, MD, PhD 2013
University of Utah

Constantine Mitsiades, MD, PhD
2014 Dana-Farber Cancer Institute

Jeffrey Mouldrem, MD 2012²²
The University of Texas
MD Anderson Cancer Center

Tarik Moroy, PhD 2015*
Institut de Recherches
Cliniques de Montreal

Markus Muschen, MD, PhD 2014
University of California,
San Francisco

Nicolas Nassar, PhD 2014
Cincinnati Children's Hospital
Medical Center

Ruben Niesvizky, MD 2013
Weill Medical College of Cornell
University

Owen O'Connor, MD, PhD 2013
Columbia University Medical Center

Tiong Ong, MD 2013
National University of Singapore

Christopher Park, MD, PhD 2014
Memorial Sloan Kettering
Cancer Center

Alessandra Pernis, MD 2014
Hospital for Special Surgery

Javier Pinilla, MD, PhD 2015*
Lee Moffitt Cancer Center
& Research Institute

Karen Rabin, MD 2014
Baylor College of Medicine

Anjana Rao, PhD 2015*
University of Michigan
Allergy and Immunology

Pavan Reddy, MD 2013
University of Michigan

Katy Rezvani, MD, PhD 2015*
The University of Texas
MD Anderson Cancer Center

¹⁶ Dr. Joanna Tober is The HM Insurance Group Special Fellow.

¹⁷ Dr. Stephen Ansell is funded in part by The Adami-Robertson Family.

¹⁸ Dr. Saro Armenian is funded in part by the California Community Foundation.

¹⁹ Dr. H. Leighton Grimes is funded in part by The Marge & Charles J. Schott Foundation.

²⁰ Dr. Thomas Loughran is funded in part by the CHMB.

²¹ Dr. Matthew Matasar is funded in part by the Jane Elissa/Charlotte Meyers Endowment Fund.

²² Jeffrey Mouldrem is the Imagine a Cure for Leukemia's Translational Researcher.

PARTNERSHIPS

James Rubenstein, MD, PhD 2014
University of California,
San Francisco

Daniela Salvemini, PhD 2013
Saint Louis University

Aaron Schimmer, MD, PhD 2015*
University Health Network

Neil Shah, MD, PhD 2013
University of California,
San Francisco

Matthew Shair, PhD 2014
President & Fellows of
Harvard College

Margaret Shipp, MD 2013
Dana-Farber Cancer Institute

Ulrich Steidl, MD, PhD 2014
Albert Einstein College of
Medicine of Yeshiva University

A. Keith Stewart, MD 2013
Mayo Clinic Arizona

Michael Thirman, MD 2013
The University of Chicago

John Timmerman, MD 2014
University of California,
Los Angeles

Steven Treon, MD, PhD 2015*
Dana-Farber Cancer Institute

David Wald, MD, PhD 2014
Case Western Reserve University

Y. Lynn Wang, MD, PhD 2013
The University of Chicago

David Wiest, PhD 2014
Fox Chase Cancer Center

Ryan Wilcox, MD, PhD 2013
University of Michigan

Catherine Wu, MD 2013²³
Dana-Farber Cancer Institute

David Wu, MD, PhD 2014
University of Washington

B. Hilda Ye, PhD 2015*
Albert Einstein College of
Medicine of Yeshiva University

Qing Yi, MD, PhD 2015*
Cleveland Clinic Foundation

Johannes Zakrzewski, MD 2015*
Memorial Sloan Kettering
Cancer Center

Peter Zandstra, PhD 2013
University of Toronto

Chengcheng Zhang, PhD 2014
The University of Texas
Southwestern Medical Center

Li Zhang, PhD 2013
University Health Network

TRANSLATIONAL RESEARCH PROGRAM: RENEWAL

Katherine Borden, PhD 2015*
University of Montreal

John Byrd, MD 2015*
The Ohio State University

John Crispino, PhD 2015*
Northwestern University

Varsha Gandhi, PhD 2014
The University of Texas
MD Anderson Cancer Center

Ronald Levy, MD 2014²⁴
The Board of Trustees of the
Leland Stanford Junior University

David Scheinberg, MD, PhD 2014
Memorial Sloan Kettering
Cancer Center

WALDENSTROM'S MACROGLOBULINEMIA PROJECTS[†]

Ruben Carrasco, MD, PhD 2014
Dana-Farber Cancer Institute

MPN CHALLENGE

Nadia Carlesso, MD, PhD 2015*
Indiana University
School of Medicine

Michael Deininger, MD 2015*
University of Utah Huntsman
Cancer Institute

Lei Ding, PhD 2015*
Columbia University
Medical Center

Angela Fleischman, MD 2015*
University of California, Irvine

Robert Kralovics, PhD 2015*
Center for Molecular Medicine of
the Austrian Academy of Sciences

Ann Mullally, MD 2015*
Harvard Medical School

Katya Ravid 2015*
Boston University
School of Medicine

Gary Reuther, PhD 2015*
H. Lee Moffit Cancer Center
& Research Institute

Jean-Luc Villeval, PhD 2015*
INSERM, Institut Pasteur (France);
Universite Catholique de Louvain
(Brussels)

Leonard Zon, MD 2015*
Boston Children's Hospital

NEW IDEA AWARD

Tarek Abbas, PhD 2015*
University of Virginia

Craig Crews, PhD 2015*
Yale University

Adam Goldfarb, MD 2015*
University of Virginia

Peter Gordon, MD, PhD 2015*
University of Minnesota

JJ Miranda, PhD 2015*
The J. David Gladstone Institutes

Matthias Stephan, MD, PhD 2015*
Fred Hutchinson
Cancer Research Center

SCREEN TO LEAD PROGRAM

Kenneth Anderson, MD 2015*
Dana-Farber Cancer Institute

Ruben Carrasco, MD, PhD 2015*
Dana-Farber Cancer Institute

Li Chai, MD 2014
Brigham & Women's Hospital

Michael Deininger, MD, PhD 2014
University of Utah Huntsman
Cancer Institute

Yali Dou, PhD 2014
University of Michigan

Kathleen Sakamoto, MD, PhD 2015*
The Board of Trustees of the
Leland Stanford Junior University

Aaron Schimmer, MD, PhD 2014
University Health Network

William Sugden, PhD 2015*
The Board of Regents of the
University of Wisconsin System

David Williams, MD 2014
Children's Hospital Boston

SPECIAL INITIATIVES

Susan Parsons, MD, MRP 2014
Tufts University

THERAPY ACCELERATION PROGRAM PARTNERSHIPS

Acetylon Pharmaceuticals, Inc.
Boston, MA

Affimed Therapeutics AG
Heidelberg, Germany

arGEN-X BV
Breda, Netherlands

BioTheryX, Inc.
Chappaqua, NY

Ivan Borrello, MD
Johns Hopkins University,
Sidney Kimmel Comprehensive
Cancer Center

Celator Pharmaceuticals, Inc.
Princeton, NJ

Asher Chanan-Khan, MD
Mayo Clinic Jacksonville

Christopher Cogle, MD
University of Florida

Constellation Pharmaceuticals, Inc.
Cambridge, MA

Curis, Inc.
Lexington, MA

Nicholas Donato, PhD
University of Michigan

Brian Druker, MD
Oregon Health &
Science University

Mark Frattini, MD, PhD
Memorial Sloan Kettering
Cancer Center

Irene Ghobrial, MD
Dana-Farber Cancer Institute

Jolanta Grembecka, PhD
University of Michigan

Anand Jillella, MD
Emory University

Holbrook Kohrt, MD, PhD
The Board of Trustees of the
Leland Stanford Junior University

The Learning Collaborative
Kansas City, KS

Ari Melnick, MD
Weill Medical College of
Cornell University

Daniel Pollyea, MD
University of Colorado

Yogen Saunthararajah, MD
Cleveland Clinic

Aaron Schimmer, MD, PhD
University Health Network

Shape Pharmaceuticals, Inc.
Cambridge, MA

Stemline Therapeutics, Inc.
New York, NY

Valor Biotherapeutics, LLC
Dallas, TX

²³ Dr. Catherine Wu is funded in part by The Jim Jacobs Charitable Foundation.

²⁴ Dr. Ronald Levy is funded in part by the Dyer Family Foundation.

* Newly awarded or renewed grants in fiscal year 2015

[†] Partner grants with the International Waldenstrom's Macroglobulinemia Foundation (IWMMF).

RESEARCH PORTFOLIOS

LLS Research Portfolios are groups of research projects organized around a specific blood cancer interest. The list below includes donors that generously invested in a specific LLS research portfolio during this fiscal year.

Acute Lymphoblastic Leukemia¹

Acute Myeloid Leukemia and Myelodysplastic Syndromes²

Chronic Lymphocytic Leukemia³

Chronic Myeloid Leukemia⁴

Hodgkin Lymphoma⁵

Immunotherapy⁶

Mantle Cell Lymphoma⁷

Myeloma and Waldenstrom Macroglobulinemia⁸

Aggressive Non-Hodgkin Lymphoma⁹

Indolent Non-Hodgkin Lymphoma¹⁰

Pediatric and Young Adult Blood Cancer¹¹

Quality of Life¹²

Stem Cell Transplantation Research Portfolio¹³

Therapy Acceleration Program¹⁴

The Harry T. Mangurian, Jr. Beat AML Project¹⁵

- 1 Acute Lymphoblastic Leukemia Research Portfolio is funded in part by Megan's Wings Foundation.
- 2 Acute Myeloid Leukemia and Myelodysplastic Syndromes Research Portfolio is funded in part by The Hildegarde D. Becher Foundation, Inc., the David Gigliotti Legacy Foundation, Mike Golner, Pat and Lou Manzi, William McNitt, Melody's Fund, and Pat and Jeff Sachs.
- 3 Chronic Lymphocytic Leukemia Research Portfolio is funded in part by Madeline and Stephen Anbinder, the George L. Shields Foundation, Inc., Sandi and Stan Kahan, Thomas Kelley, and Robin D. and Jonathan Klein.
- 4 Chronic Myeloid Leukemia Research Portfolio is funded in part by Leslie & Dr. Larry Nance and Charles Foundation and Becky Godchaux.
- 5 Hodgkin Lymphoma Research Portfolio is funded in part by Baltimore Tour de Court XIX in memory of Rachel Minkove, and Praxair, Inc., Janet & Alex Boggs and Jami and Edward Levy.
- 6 Immunotherapy Research Portfolio is funded in part by Andrew F. Gulli.
- 7 Mantle Cell Lymphoma Research Portfolio is funded in part by Andrew F. Gulli.
- 8 Myeloma and Waldenstrom Macroglobulinemia Research Portfolio is funded in part by the Names Family Foundation.
- 9 Aggressive Non-Hodgkin Lymphoma Research Portfolio is funded in part by Lisa and Craig Hawkins and the Slice of Lime Foundation.
- 10 Indolent Non-Hodgkin Lymphoma Research Portfolio is funded in part by Nonnie and John Barbey, Susan and Jay Clark, Tom Harrison, Chris Kolb, Cristine and Timothy Lindenfelser, Cambria and Brian Reinsborough, Lois and Jerry Rosenblum, Beth Salter and Gloria, Ellie and Mark Weissberg.
- 11 Pediatric and Young Adult Blood Cancer Research Portfolio is funded in part by the A.C.E. Family Foundation, the Alverin M. Cornell Foundation, Jennifer and David Comar, Franklin American Mortgage Company, The Hershey Company, Hockey Fights Cancer, Parents Against Leukemia, Cynthia & Steven Rigby, Take a Swim Against Cancer - Bucks County Aquatic Swim Teams, Team Ryan, The Thomas and Agnes Carvel Foundation, the Virginia Tech FarmHouse Fraternity, and Yvonne and Tamer Youssef.
- 12 Quality of Life Research Portfolio is funded in part by The Cherry Picker Foundation, The Escher Foundation - Doris J.W. Escher, MD, the Hamill Family Trust, and The Hildegarde D. Becher Foundation, Inc.
- 13 Stem Cell Transplantation Research Portfolio is funded in part by the Rogers Family Foundation.
- 14 Therapy Acceleration Program is funded in part by Debbie and Patrick Allender, Jean and C.E. Andrews, Dr. Evelyn Bata, Valorie and Mel Booth, Elizabeth and Bruce Bowen, F.M. Kirby Foundation, Inc., Marianne Keler & Michael Kershaw, Melryder Foundation, Emily and Neil Kishter, the Love Always Fund, The Paul E. Singer Family Foundation, Sherry and Steve Mayer, The Phase Foundation, The Sleep Family, Lois and Jerry Rosenblum, and the Virginia Sheldon Jerome Foundation.
- 15 The Harry T. Mangurian, Jr. Beat AML Project is funded in part by The Altschul Foundation-Reichman Memorial, Joe Azrack, George Baker, Bear Down, Alexandra Mayes Birnbaum, Hill Blalock, Frona A. Brown, Ed.D., the Carol Lavin Bernick Family Foundation, Eileen Burg, Mary Kay and John Chlebina, Liz and Michael Copley, Julie and Roger Davenport, Judith Davis, Thomas Fitzgerald, The For Julie Foundation, Inc., Lynn and Bob Goldschmidt, David Graiss, The Harry T. Mangurian, Jr. Foundation, Inc., John & Frances Beck Fund, Bill Jones, Amy Katz, Mary Beth and Christopher Keams, Cristina Kellenyi and Manny Garcia, John Kellenyi, Ann and Mark Kenyon, Madding King, Paul Leinwand, Steven Lieblich, Craig Lucas, Katie and Harris Lydon, The Lymphomaniacs, Clyde S. McGregor and Leann Pedersen-Pope, Jeffrey McMillan and Janine Kiely, NYC Board of Trustees, The Pamela B. Katten Memorial Leukemia Research Foundation, The Pinkos Family/Team Grant, Donald I. Porteous, the Rally Foundation for Childhood Cancer Research, Valentina and Jon Raleigh, The Randy and Deborah Daniel Family Charitable Foundation, The James H. Reid, Jr. Family, Bobbi and Robert Reitzes, the Robert E. Gallagher Charitable Trust, The Robert H. Lyon Leukemia Foundation, the ROMA Charitable Foundation, David Rosenfeld, Paul and Joan Rubschlager Foundation, Pat and Jeff Sachs, Stephen Scherr, Spike TV, Mona Carlton Stogner and Grey Stogner, Elizabeth and Michael Sweeney, Team Blumenfeld & Waterman, Robert Van Grover, Joseph and Drenda Vijuk Foundation, Robert Weisenfeld, Michael Weiss, Kenneth Whitney, and an anonymous donor.

ADVISORS

MEDICAL + SCIENTIFIC AFFAIRS COMMITTEE

Steven Rosen, MD
City of Hope
Chair

Steven Bernstein, MD
University of Rochester
Medical Center

Alexandra Mayes Birnbaum
Peartree Publishing

James Bradner, MD
Dana-Farber Cancer Institute

Alan D'Andrea
Dana-Farber Cancer Institute

James H. Davis, PhD, JD

Sandra Horning, MD
Genentech, Inc.

Catriona Jamieson, MD, PhD
University of California, San Diego

Ross Levine
Memorial Sloan Kettering
Cancer Center

Jonathan Licht, MD
Northwestern University

Alan List, MD
H. Lee Moffitt Cancer Center

Susan M. O'Brien, MD
The University of Texas
MD Anderson Cancer Center

Owen O'Connor, MD, PhD
Columbia University
Medical Center

Franklin O. Smith, MD
University of Cincinnati

A. Keith Stewart
Mayo Clinic and Foundation

Cheryl Willman, MD
University of New Mexico

THERAPY ACCELERATION PROGRAM COMMITTEE

Dana Callow, MBA
Boston Millennium Partners
Chair

James Bradner, MD
Dana-Farber Cancer Institute

Joseph Catino, PhD
Retired from Bayer

C. Casey Cunningham, MD
Santé Ventures

James H. Davis, PhD, JD
Retired from Human Genome
Sciences, Inc.

Ian W. Flinn, MD, PhD
Tennessee Oncology

Jennifer Gordon, PhD, JD
Paul, Weiss, Rifkind,
Wharton & Garrison LLP

Ross Levine, MD
Memorial Sloan Kettering
Cancer Center

Susan M. O'Brien, MD
The University of Texas
MD Anderson Cancer Center

J. Fred Pritchard, PhD
Celerion

ENDOWMENT FUNDS

The Bill Beattie Memorial
Endowment Fund (Alberta)

Mary & Robert Bronstein
Memorial Fund

The Virginia Major Brooks
Memorial Endowment Fund

de Villiers Endowment Fund

Thomas M. Ford Memorial Fund

GlaxoSmithKline Foundation—
Gertrude B. Elion
Endowment Fund

GlaxoSmithKline, Inc.
Research Fund

Jim Jacobs Leukemia
Research Fund

The Rachel Kudish Fund

Jane Elissa/Charlotte Meyers
Endowment Fund

The Rae Endowment Fund
(Ontario)

Vrushali Ranadive Fellowship Fund

Reich Endowment Fund

The UFCW (Canada)
Endowment Fund

DONORS

The below listing is made up of individuals, foundations and corporations that generously supported LLS's mission during this fiscal year.

LEADERSHIP CIRCLE \$1,000,000 AND ABOVE

Barclays
The Beer Store
Burlington
Celgene Corporation **PS PP R C**
Edward P. Evans Foundation
Genentech, Inc. **PS PP R C**
The Harry T. Mangurian, Jr. Foundation, Inc.
Millennium: The Takeda Oncology Company **PS PP R C**
Nike
Novartis Pharmaceuticals Corporation **PS PP R C**
The Olive Garden Italian Restaurant
The Paul E. Singer Family Foundation*
Pharmacyclics/Janssen Pharmaceutical Companies **PS PP R C**
United Food and Commercial Workers International Union Canada/TUAC
United Food and Commercial Workers Union (UFCW)

CHAMPION \$500,000 – \$999,999

Ethel & Bernard Garil*
Kathryn & Rush Limbaugh
Michael Garil Fund for Leukemia Research at the Dana-Farber Cancer Institute
PVH
Team Charles Esten
Teva Pharmaceuticals **PS PP R C**

VISIONARY \$250,000 – \$499,999

Austaco, Ltd.
Carter's, Inc.
Elbit Systems of America
F.M. Kirby Foundation, Inc.
Foundation Beyond Belief
Global Franchise Group
Great American Cookies
Lang/Stiglitz Family Fund
Cristine & Timothy Lindenfelser*
MaggieMoo's Ice Cream & Treatery
Marble Slab Creamery
The Orokawa Foundation
Pfizer, Inc. **PS PP R**
Pretzelmaker
Salesforce.com
Spectrum Pharmaceuticals, Inc. **PS C**
Stater Bros. Charities
Thomas J. and Gerd Perkins Foundation
Kathryn & Leo Vecellio*
Wells Fargo

PATRON \$100,000 – \$249,999

ADP
Alex and Ani
The Amgen Foundation
Astellas USA Foundation
Baker Botts L.L.P.
Baptist Health South Florida
Dr. Evelyn Bata
Douglas H. Baughman
BDO
Biogen Idec **C**
The Blackstone Charitable Foundation
BMC
Bristol-Myers Squibb Company **PS C**

Janice & Peter Brock*
BTIG, LLC
CA Technologies
California Community Foundation*
Cancer Treatment Centers of America
CareFirst BlueCross BlueShield
CHMB
The Coleman Foundation*
Community Health Charities of New England
Cruise Planners - American Express Travel
Deloitte
Ernst & Young LLP
EZCorp
FIS Foundation
Fleming's Prime Steakhouse & Wine Bar
GEICO
Patricia & Christos Giannoulis
Gilead Sciences, Inc. **C**
Global Traveler
Google
The Harry & Jeanette Weinberg Foundation, Inc.
Imagine a Cure for Leukemia
Jason's Deli
KPMG LLP
W. Robert Lappin Trust
LLS New York City Chapter Board of Trustees
The Marge & Charles J. Schott Foundation*
Clyde S. McGregor & LeAnn Pedersen-Pope in memory of Joan Kowing McGregor
Mercedes Benz
Merchandise Pickup Service, Inc.
Missouri Foundation for Health*
Onyx Pharmaceuticals, Inc. **PS C**
The Pamela B. Katten Memorial Leukemia Research Foundation
PhRMA **C**
Donald I. Porteous

PwC
Nancy C. & Richard Rogers
Sarah Cannon
Blood Cancer Network
Stephen Scherr
Silicon Valley Bank
Spike TV
Daneen & Charles Stiefel
TIAA-CREF
Toyota
Vistar
VITAS Innovative Hospice Care
Walgreens
Gloria, Ellie & Mark Weissberg
Anonymous (1)

INNOVATOR \$50,000 – \$99,999

ABM Janitorial Services - Midwest LLC
A.C.E. Family Foundation
Accenture
Adami-Robertson Family*
Alon 7-Eleven
Alto-Shaam, Inc.
American Airlines
Jean & C.E. Andrews*
Anthony and Jeanne Pritzker Family Foundation
Bank of America
Janet & Alex Boggs*
Booz Allen Hamilton
Briggs Equipment Services
Mr. & Mrs. Morris Brown
C.H. Robinson Worldwide, Inc.
Rita Cavanagh & Gerald Kafka
Citrix Systems, Inc.
Comcast Spotlight
Continental Resources, Inc.
DARCARS
Liz & Michael Copley*
Sharon Dippel
Doctor's Choice Pharmacy

Englefield Oil Co.
Enmark Stations, Inc.
Florida Cancer Specialists & Research Institute
Florida Panthers Foundation
The For Julie Foundation, Inc.
Garden City Turkey Trot
GiveSmart US, Inc.
Andrew F. Gulli
The Hamill Family Trust
Thomas E. Hancock
Hargrove
Pete Harman
The Hildegard D. Becher Foundation, Inc.
The HM Insurance Group
Host Hotels & Resorts
John Hyland
Incyte Corporation **PS C**
Industrial Alliance Insurance and Financial Services, Inc.
Infor Global Solutions, Inc.
The Jake Wetchler Foundation
John & Frances Beck Fund
Kent Joshi
John Kellenyi
Emily & Neil Kishter
The Kroger Co.
Laborers' Charitable Foundation
Lehigh Valley Restaurant Group
Paul Leinwand
Steven Lieblich
Lighthouse Investment Partners, LLC
Michael Maggi
Gina Manos
Marsh Supermarkets, Inc.
Melody's Fund
Metzger Law Group
Microsoft
Mary Miner
Gary Moy
Native American Cash Systems Florida, Inc.

New York Community Bancorp
Parents Against Leukemia
Park Foundation
Phillips-Van Heusen Foundation, Inc.
Ping Y. Tai Foundation
Praxair, Inc.
PRG
Promontory Financial Group, LLC
Quiznos
Rally Foundation for Childhood Cancer Research*
Laura Randolph & Jerome Oakley
Reignwood Group - Dr. Chanchai Cambria & Brian Reinsborough
Ritchie Bros. Auctioneers
Robert E. Gallagher Charitable Trust
Lois & Jerry Rosenblum
Salt River Pima-Maricopa Indian Community
Sarver Charitable Trust
Seattle Genetics, Inc. **C**
SGI
Sivage/Greater San Antonio Builders Association
SMART Modular Technologies
Southern California Gas Company
Diana & Todd Stiefel
Sylvan Learning Center
Tap Cancer Out
Toll Brothers, Inc.
Washingtonian Magazine
Wawa, Inc.
Yahoo!
Anonymous (2)

PHARMACEUTICAL FUNDING LEGEND

PS Patient Services
PP Public Policy
R Research
C Campaign

* Denotes multi-year commitment

DONORS (continued)



ADVOCATE

\$25,000 – \$49,999

Michael Adams
Debbie & Patrick Allender
Alverin M. Cornell Foundation
AMC Cares Foundation
Ameren Corporation
AMERICAN SYSTEMS
Amon G. Carter Foundation
Madeline & Stephen Anbinder
Annaly Capital Management
Anybill
Aon Foundation
Automatic Fire Protection, Inc.
Baker Tilly
Baltimore Tour de Court XIX in memory of Rachel Minkove
Bartlett Cocke General Contractors
BASF - The Chemical Company
Baton Rouge Area Foundation
Baylor University
Baylor Scott & White Health System
BB&T Bank
Berghoef/Boyle Foundation
Bert Smith & Co.
Big Steaks Management, LLC
BIO
BMO Harris Bank
Mel & Valorie Booth*
Boscov's
Bruce Bocina
BrassCraft
Brayton Purcell, LLP

Andrew Brock
Brant Bukowsky
Jeff Burch - Hot Ticket Racing
Caisse de bienfaisance des employés et retraités du CN
Anthony Campbell
Matthew Campbell
Capitol File Magazine
Carlos Batista Foundation
CBRE - New England
CFACQ
Charity Buzz
Chiaromonte Construction Company
Circle City Foundation
Kathy & Patrick Cocherl
Color Me Rad Races
Comcast
Comedy Central
Commerce Bank
Community Health Charities of Kansas & Missouri
Community Health Charities of Minnesota
Crane Fund for Widows and Children
Dana-Farber Cancer Institute
Deutsche Bank
Samantha & Timothy Durst*
EBAY
Edward G. & Kathryn E. Mader Foundation
Family & Friends of Bebe Fineman
Florentine R. Camenish Trust
Cristina Muñoz Flores
Franklin American Mortgage Company
Piera Freitag

Furniture Fair
Vicky Garcia & Carol Alexander
Generac Power Systems, Inc.
General Dynamics Information Technology
Gila River Casinos
GovPlace
Grace Heritage Corporation - Nowell Foundation
The Greater Milwaukee Foundation, Inc.
Jeff Gusinow
Harry Harrison & Amy Nauiakas
Sharon Hathaway
The HEADstrong Foundation
HealthyFit
Al G. Hill, Jr.
Ken Hitz
Honored Hero Run
Houlihan Lawrence
ICAP Services North America, LLC
Independent Health
InfoReliance Corporation
InquisIT
J & J Development, Inc.
J.T. Tai & Co Foundation, Inc.
Amie & Tony James
The Jim Jacobs Charitable Foundation
Kaiser Permanente 
Aileen Kass
KBR, Inc.
Kent's Run
Kenworth Hazmat
Kmart Puerto Rico
Dave Labuda
Don C. & Diane S. Lake Family

Left Hand Brewing Foundation
Leon Medical Centers
Lilly USA, LLC 
The Lintner Foundation
The Lipstein Family Foundation
Lunardi's Supermarket, Inc.
Lundbeck Canada
Madison Classic
Magid Family Fund
Pat & Lou Manzi
Electra & Bruce Martin
Roxanne & Rocco Martino
Maxim Group LLC
Mayo Foundation for Medical Information and Research
MedImmune, LLC 
Melryder Foundation*
The Memorial Foundation, Inc.
Menkes Charity Golf Classic
Mercedes Benz of Fresno
Michael C. Fina
Michael Marks Family Foundation
Miles & Stockbridge
NAIOP Chicago
NetJets
Newcap, Inc.
Northrop Grumman
Northside Hospital Cancer Institute
Norton Rose Fulbright
Lynne & Greg O'Brien
Offshore Sailing School
OHSU
Orden, Berkett, Flesh & Sassover Families
Penny Packer
Peoples Natural Gas

PFG / Vistar
Philadelphia Multiple Myeloma Networking Group
Reliant, an NRG Company
Rhulen Rock Hill Run & Ramble
JR Rickert
Riemer & Braunstein LLP
Roche Canada
Roditti Family Fund
ROMA Charitable Foundation
RPA Advisors LLC
SAIC
Sailing World/Cruising World Magazines
SanDisk Corporation
Mr. & Mrs. John F. Scarpa
Scott Safety
Seminole Tribe of Florida
Beth & David Shaw
Charlie Sheen
Silicon Valley Community Foundation
Marilyn & Jim Simons
Elaine S. Smith
Bonnie & Stephen Spiegle
St. Joseph's/Candler
Noa Staryk
Mona Carlton Stogner & Grey Stogner
Symantec Corporation
Team Telus Cares
Ted Britt Automotive Group
Judy & Michael H. Thomas
Mr. & Mrs. Donald Trump
Ultimate Software
Valero Energy Corporation
VCU Medical Center

Betty Vest
Viacom, Inc.
Virginia Sheldon Jerome Foundation
Wallace H. Coulter Foundation
WASH-FM
Washington Business Journal
West New York Restoration of CT, Inc.
Sally & Geoffrey White
William Rich Foundation
Willis Foundation
World Wide Technology, Inc.
WTOP Radio
Stanley Zax
Anonymous (8)

GIVING CIRCLE

\$10,000 – \$24,999

1 Source Consulting
21st Century Fox
21st Century Insurance
ABC 7/WJLA-TV
Susanne Abramowitz
Ann Adams
Jan & Warren Adelson
AE Charitable Foundation
AFD Contract Furniture, Inc.
Agero Administrative Service Corp.
Air Products Foundation
Jamail Ajaj
Akin, Gump, Strauss Hauer & Feld, LLP
Albert & Elaine Borchard Foundation
Anne & Doug Albrecht

Alice Ann Bien Foundation	Mr. & Mrs. Michael Azeez	Blumenfeld Development Group	Capital One Bank	Clark Construction Group, LLC	Ark 31 Foundation
Alliance Data Systems, Inc.	Anna & Dean Backer	Susan & Ed Blumenfeld	Nick Caporella	Clark Family Charitable Fund	The Cottrell Foundation
Allied Capital & Development of South Florida	BAE Systems	BMW of San Antonio	Capstone Advisory Group, LLC	Susan & Jay Clark	Courtney Knight Gaines Foundation, Inc.
Allmond & Company LLC	George Baker	Michele Boal	Carbide Concepts Company LLC	Lonnie & Bobbi Clayton	Covington & Burling LLP
The Altschul Foundation - Reichman Memorial	Bank of America Merrill Lynch	Boehringer Ingelheim Pharmaceuticals, Inc. ^R	Cardinal Solutions Group, LLC	Cleary Gottlieb Steen & Hamilton LLP	Cox Family of Brownlee—SK Foundation
Alvin J. Siteman Cancer Center	Banner MD Anderson Cancer Center	Bognar and Company, Inc.	CARFAX	Isobel & Bruce Cleland	Cracker Barrel
Ambit Energy	The Baratta Family Fund	Bonadelle Neighborhoods	Dana & David Carlos	Clune Construction Company	Amy & Daron Cramer
American Direct Marketing Resources, LLC	Barbara & William Rosenthal Family Foundation	Elizabeth & Bruce Bowen	Carnival Cruise	Coach Foundation, Inc.	Cravath, Swaine & Moore LLP
American Electric Systems	Nonnie & John Barbey	Gerry & John Boyle	Carol Lavin Bernick Family Foundation	Coastal Bank & Trust	Credit Suisse
American Endowment Foundation	Barclaycard US	Brampton Minor Baseball, Inc.	Scott Carroll & Erin O'Grady	Rhodau Cobb - The Cobb Foundation	Cresa Cares, Inc.
American Family Care	Michael Bartschat	Brandywine Realty Trust	Holly & Richard Caserta	CoBiz Financial	Crockett Facilities Services, Inc.
America's Charities	The Batchelor Foundation, Inc.	Brewers of Indiana Guild	Ben Cassell	Bert Cohen	Kevin Cronin
Amgen ^R	BBL Construction Services	The Briard Group	CBIZ	Lawrence Cohen	CrossCountry Consulting
Anadarko Petroleum Corporation	BD Biosciences	Faye C. Briggs	CBRE	Coldwell Banker Residential Brokerage	Cruise Industry Charitable Foundation
Anning Johnson & H&D Mechanical	Becky & Lewis Brunswick Fund	Brooks-Mathews Foundation	Celator Pharmaceuticals ^C	Cole, Scott & Kissane P.A.	CTIA - The Wireless Association
Anthem Blue Cross & Blue Shield	Belvedere Cove Foundation & Cromar Foundation	Brown & Gould	CenterPoint Energy	The Colonial Group	CWCcapital
Aon Activities Committee	Ben Carter Enterprises	Frona A. Brown, Ed.D.	CentiMark	Jennifer & David Comar	Bill Dagiantis
Apache Corporation	Adam Bence	Reginald Brown	Centro - Charleen's Angels	Combined Health Agencies	Dallas Stars Foundation
Apollo Hospitals	Bender Foundation	Daniel Bruckner	Century Elevator Maintenance Corp.	Margaret Comfort	Carole & Robert Daly
Ares Management & Adler Realty Services	Mary & Jorge Benitez	Larry Buchalter	Cerner Corporation	Community Foundation of New Jersey	The Damon Giglio Foundation
ARIAD Pharmaceuticals, Inc. ^C	Johanna Berkman & Manny Weintraub	BuildASign.com	CH2M Hill	Community Health Charities of Iowa	Danaher Corporation
Kate & Charles Arnold	Berkshire Bank	James Burgin	Charles Foundation and Becky Godchaux	Compatriot Capital	Danford Foundation
Assurant Foundation	Bernadette Schaeffler Collection	Laurie Burns	Rhoda & David Chase	Comstor	Julie & Roger Davenport
Assurant Specialty Property	Jason Bice	Burnt Orange Benefit	The Cherry Picker Foundation	Michael Conlon	David Adams Memorial Fund
Astellas Pharma US, Inc. ^C	Alexandra Mayes Birnbaum	Michael Burrage	Chester Valley Golf Club	Robyn & Don Conlon	David Gigliotti Legacy Foundation
Astex Pharmaceuticals ^C	Bisnow	Butler Family Foundation	Children's Hospital & Medical Center	Contemporary Electric Services, Inc	David Yurman
Augusta Oncology Associates	BJC HealthCare	Laura & John Byrd	Mary Kay & John Chlebina	Continental Food Management, Inc.	The Davis Family Foundation
AutoTrader.com	Black Dog Charity	C. Jay Moorhead Foundation	Justin Chueh	Cook Children's Health Care System	Davis Love Foundation
Armen Avanesians	Blue Buffalo Foundation for Cancer Research	C.J. Coakley Co., Inc.	Church & Dwight Co., Inc.	Cora and John H. Davis Foundation	Davis Polk & Wardwell
Avella Specialty Pharmacy	Blue Canopy	CA Technologies Matching Gifts Program	Cisco Systems	Cortland Finnegan	James H. Davis, PhD, JD
Avnet	Blue Cross	Becky & Dana Callow Family	Citizens for Carolyn H. Krause		Dayton Interventional Radiology
Sine & John Ayres	Blue Cross and Blue Shield of Mississippi	Calvert Foundation	City Barbeque		Dayton Outpatient Center
		Dillon Cameron	City of Batavia		The de Moya Group, Inc.
		Michael Campbell			

DONORS (continued)

Deans Knight Capital Management Ltd.	John Eidel	First Coast Honda Dealers	The Geaton & Joann Decesaris Family Foundation, Inc.	Corporation	Houlihan Lokey
Dear Jack Foundation	Steven Eisenstadt	First Service Federal Credit Union	General Dynamics Advanced Information Systems	Greenberg Gibbons	Howard Family Foundation
Joe DeCosmo	El Pomar Foundation	Firstenberg Foundation	General Motors Company	Greenberg Traurig, LLP	Ben Howard
Dennis M. Jones Family Foundation	Element Financial Corporation	Bruce Fletcher	Gensler & Rand	Grip It & Rip It	Hoxworth Blood Center
Denver Petroleum Club	David Elliott	Flexco Fleet Services	The GEO Group, Inc.	Ricki & Dennis Grossman	Hy-Vee, Inc.
Detroit Auto Dealers Association	Embassy of the United Arab Emirates	Florida Panthers Hockey Club LTD	The George F. And Myra Shaskan Foundation, Inc.	Seth Grossman	IBC Bank
Amy Diaz	EMC2	Flushing Bank	George L. Shields Foundation, Inc.	Groupe LMT	IBM
John DiClemente	Emergent BioSolutions Inc.	FMC Corporation	Georgia Power Foundation, Inc.	Gulf Coast Bank & Trust Company	Gabriel Iglesias
Digital Print Solutions	Emerson	Foley & Lardner, LLP	Georgia Regents University	HAC, Inc.	Immunor, Inc. 
Discount Tire Co.	EN Engineering	Forest City Ratner Companies	GetWellNetwork, Inc.	The Handlery Foundation	In Memory of Brendan Kelly
Dixon Family Trust	The Enrichment Foundation	Forevermark	Giant Food	Hansen Bros. Enterprises	Independence Blue Cross
DLA Piper LLP	Entergy Corporation	Fossil, Inc.	Giants Community Fund	Haque Insurance Agency	Ingram Micro
Dodge Jones Foundation	Enterprise Holdings Foundation	Fox5	Gibson, Dunn & Crutcher LLP	Harkins Builders	Insulators International Health Hazard Fund
Dominion Mechanical	Enterprise Holdings, Inc.	Fred Smith Plumbing & Heating Company	Darin Gillenwater	Tom Harrison - In Loving Memory of Sylvia Morningstar Harrison	Intevac, Inc.
Downing Wellhead Equipment, LLC	Enterprise Rent-A-Car	Freedom Financial Group, LLC	GlaxoSmithKline 	Harry C. Moores Foundation	Iron Bow
Dr. Gerald and Paula McNichols Family Foundation	Epic	The Fresno/Clovis New Car Dealers Association	Global Electronic Technology	The Hartley Company	ISN Software Corp.
DreamWorks Animation LLC	The Escher Foundation - Doris J.W. Escher, MD	Elyssa Friedland	Global Prairie	Lisa & Craig Hawkins	Ivie & Associates, Inc.
Billie Ruth Drummond	ESPN980	Beth & Josh Friedman	The Gold-Diggers, Inc.	H-E-B	J & J Shared Services
Candy Duncan	Estridge Family Foundation	Marti & Steven Friedman	Golden Corral	Helen W. Bell Charitable Foundation	J.B. Fuqua Foundation
Thomas Dunham	EXL	Frieze Harley-Davidson	Goldman Sachs	The Helis Foundation	Ellen Jackson
The Durst Organization	Experian	FTI Consulting, Inc.	Goldman Sachs Gives	Timothy Henkel	Janssen Biotech, Inc. 
Dyer Family Foundation	Express Scripts, Inc.	Fullerton Firefighters Association	Mike Golner	Henry J. Lee Distributors, LLC	Jared Coones Pumpkin Run
Dynaelectric and WE Bowers	Faisal Rehman Medicine Professional Corporation	Fundación Segarra Boerman e Hijos, Inc.	Thomas Goodmanson	Hercules Corp.	Jazz Pharmaceuticals plc 
EagleBank	Family of Beth Victor	Enrico S. Gaglioti	Becky & Brett Gordon	The Hershey Company	JDP Mechanical, Inc.
The Earl and Brenda Shapiro Foundation	Fansler Foundation	GAI Consultants, Inc.	Gosling's Rum	Hewlett-Packard	Jeanette & H. Peter Kriender Charitable Trust
Eastdil Secured, LLC	Kristopher Farmer	Gamma Murs & Fenetres International, Inc.	The Grainger Foundation	HGST	Richard Jeanneret
Deane Eastwood	FarmerMac	GAP Inc.	David Grais	Highstar Capital	Jefferies & Company, Inc.
Ed & H Pillsbury Foundation	Farmers Underwriters Association	Israel Garcia	Grant Thornton LLP	the Hill Group	Jewish Community Foundation of the West
Ed Rachal Foundation	Father Serra Catholic School	Gartland & Mellina Group	Alyson Grasso	Marcy & Donnie Hill	The JIAN Group, LLC
Edgar A. Thronson Foundation	Brad Feld	Richard Gartner	William Graves	Hines Interests Limited Partnership	The Jim Quay Memorial Fund
Edith M. Schweckendieck Trusts	Jim Ferguson	Gavin/Solmonese LLC	Great American Insurance Company	HireStrategy	Joan C. Ray Charitable Foundation
EEReed Construction	Finish Line Physical Therapy	GE	Greater Los Angeles New Car Dealers Association	HITT Contracting, Inc.	Gary Jobson - Jobson Sailing
	First American Title Insurance Company	GE Johnson Construction Company	Greek Orthodox Housing	Hockey Fights Cancer	Jochum-Moll Foundation
				Hogan Lovells LLP	John & Mary Franklin Foundation
				HOT 99.5	

The John G. Rangos, Sr. Charitable Foundation	KJ's Cancer Sucks Party	Harvey Lowe	Kim & Matthew Mausser	Morgan Borszcz Consulting	Ober Kaler
John Stetz Machine Shop	Robin D. & Jonathan Klein	Lowell Homes, Inc.	Sherry & Steve Mayer*	Morgan Stanley	Oddo Development
Johnson & Johnson	Kolache Factory	Craig Lucas	Maynard Family Foundation	Morgan, Lewis & Bockius LLP	OfficeMax
Jennifer Johnston	Chris Kolb	Lucas Family Foundation, Inc.	Mays Family Foundation	MorganFranklin	The Offterdinger Family
Joseph & Drenda Vijuk Foundation	Cecilia Koons	M&T Bank	Mary E. McCaul	Morley	Old Mutual
Joseph & Marion L. Mitola Family Fund	Koons Lexus of Wilmington/ CARFAX	M.A. Mortenson Company	MCCI Medical Group	Lara & George Moynihan	Walt Oliver
Joseph R. Daly Foundation	Koons of Silver Spring	M7 Aerospace	McCownGordon Construction	MSC Industrial Direct Co., Inc.	OneSource Distributors, LLC
The June and Cecil McDole Charitable Fund	Koons Tysons Toyota	Mack Madness, Inc.	Laura & Paul McDaniel	Elizabeth M. Mungo	Opus Bank
K & D Group, Inc.	Sherry & Thomas Koski	Macquarie Group Foundation	Marie & Paul McDonough	Kathryn & James Murdoch	Oracle
K2 Intelligence	Michael Koss	Macy's	McKenna Long & Aldridge LLP	Muriel Gertner Trust	ORIX Foundation
Kaelin Captain's Cup	The Kroger Co. Foundation	The Magnolia Foundation	McKesson	Michael Murray	Oxford Development Company
Sandi & Stan Kahan	Kroll Bond Rating Agency, Inc.	Bob Maher	Theresa McKinnon	Muskin Family Foundation	Ozark Motor Lines, Inc.
Jason Kahrman	Lynn & Jules Kroll	Joshua Mahoney	The McLelland Family Foundation	Names Family Foundation	Pacific Design Group, LLC
James M. Kaloyanides	KST Data, Inc.	Major Hospital	William McNitt	Leslie & Dr. Larry Nance	Pacific Union
Susan & Daniel Kane	Micah Lacher	Major League Soccer Players Union	Meester Family Foundation	National Cooperative Services Corporation (NCSC)	Padgett Stratemann
Amy Katz	Ladish Co. Foundation	William Maloney	Megan's Wings Foundation	National Philanthropic Foundation	PAR Electrical Contractors, Inc.
Michael Katz	Kathy & Michael Ladra	The Mammel Foundation	Sanjay Mehrotra	Nestle Purina PetCare	Paramount Farms
KBW: A Stifel Company	Mary Larsen	Manatt, Phelps & Phillips, LLP	Memorial Healthcare System	NetApp	Park Place Motorcars
Kearney & Company	Latham & Watkins LLP	Manhattan Associates	MERCK & Co., Inc. 	The Netter Foundation, Inc.	Passport Capital
Mary Beth & Christopher Kearns	Lauth	The Mapp Family Foundation	Meritor, Inc.	New York Community Bank	Paul & Joan Rubschlager Foundation
Marianne Keler & Michael Kershow	The Laverna Hahn Charitable Trust	Marie Lamfrom Foundation	Michael & Son Services, Inc.	Bonni & Ken Newton	The Paul B. Greetin and Beryl S. Greetin Foundation, Inc.
Thomas Kelley	Patrick Law	Mariner Real Estate Management	Emily & Thomas Michaud	NFL Foundation	Paul Hastings
The Kelly Family	Learjet Employees Care Fund	Lois Markovich	Michelle Lunn Hope Foundation	Nidec Motor Corporation	PCMA
Emily Thomas Kendrick	Mary Ledding	The Marksmen Company	MICROS Systems, Inc.	NOCO	Peake BMW
Douglas R. Kenny & Family	Brian Lee	Marriott	Milbank, Tweed, Hadley & McCloy LLP	Linda & Guy Nohra	Peck Madigan Jones & Stewart, Inc.
Kenyon Charitable Foundation	Leon S. Peters Foundation	Raymond J. Marszalowicz	Mr. and Mrs. Andrew Miller	North Sails	Pennant Foods, LLC
Ann & Mark Kenyon	Levin Family Foundation	Robert Marvin	Ms. Hermé de Wyman Miro	North Shore LIJ	PEPCO
The Kerins Family	Jami & Edward Levy	Maryland State Bar Association - Young Lawyers Section	Mitsubishi Hitachi Power Systems	Northern Trust Corporation	PepsiCo
Kickin' The Cancer Blues - The Liz Bohman Foundation	Andrew J. Lewis, Jr.	Marylou's Coffee	Alan Mittleman	Northwestern Mutual	Performance Automotive Network
Kids 'R' Kids International, Inc.	The Lilly Foundation	Massapequa Youth Lacrosse Club	Lori Mody	Northwestern Mutual Foundation	Markus Persson
King & Spalding, LLP	The Lipman Family	Nicholas Mastroianni, III	Moffitt Cancer Center & Research Institute	Nottingham Spirk	Adrian Peterson
Stuart Kipnes	Jim Lippman	Ted Mathas	Momentum Microsystems, Inc.	NPL Construction Company	Donita & Sheldon Petersen
Kim & Larry Kittoe	Live Nation Worldwide, Inc.	MATRIX Software	Moore Van Allen	Morgan O'Brien	PGA TOUR Superstore
	Lori A. Loo	MAXIMUS Foundation	Robert Moore	Peter O'Sullivan	PGT Trucking, Inc.
	Wendy Lotz				

DONORS (continued)

The Phase Foundation	Steven Rainey	Mishel & Greg Rohl	Sessions, Fishman, Nathan & Israel, LLC	Stanley Korshak	Texas Instruments
Thomas Philbrick	The Randy and Deborah Daniel Family Charitable Foundation	The Romulus T. Weatherman Memorial Fund	Carl Sewell	State Street Corporation	Texas Neurosciences Institute
The Phyllis M. Coors Foundation	Paul Raphael	Rope for Hope	Shade Tree Service Company	Jerre Stead	The Inc.
Pillsbury Winthrop Shaw Pittman LLP	Mary Virginia Rawe	Royals Charities Fund	Shearman & Sterling LLP	Phil Steel	Théâtre Saint-Bruno Players
Pimco	Ray Catena Auto Group	Rye YMCA	Ira Sherman	Donald Steiner	The Thomas and Agnes Carvel Foundation
Plaid Pantries, Inc.	Real Estate One Foundation	S&S Ventures	Sherrard Kuzz LLP	Sterne, Kessler, Goldstein & Fox P.L.L.C.	Thompson Coburn
Planet of Peace	Red Robin Lehigh Valley Restaurant Group	Jeffrey D. Sachs	The Shin Foundation	Barbara Stiefel	Thompson, Habib & Denison, Inc.
Julie & Marc Platt and Family	Reece Holbrook Win Anyway Foundation, Inc.	Pat & Jeff Sachs	Shiseido Group USA	Stifel	Mary Thompson
PNC Bank	Constance M. Reed	SAFE Credit Union	Vijay & Ram Shriram	Stone Bridge Iron & Steel, Inc.	Thoroughbred Title Services
PNC Real Estate	Kyle Reed	Safeway Inc.	Sidley Austin LLP	Stonebridge Companies	Tiber Creek Partners, LLC
Polk Brothers Foundation	Mark Regante	Lauren & John Salata	The Sidney, Milton and Leoma Simon Foundation	Studley	Tigerfight Foundation
Polsinelli PC	The James H. Reid, Jr. Family	Joseph Salley	Julie E. Silcock	Pam & Patrick Sullivan	TimeSaver Food Stores Co.
Popeyes Louisiana Kitchen, Inc.	Bobbi & Robert Reitzes	Beth Salter	Gil Simonetti III	SunTrust Bank	Tishman Speyer
Popular Community Bank	Reliance Trust	Harvey Saltzman	Neil Simpkins	SureTec	Tishman, an AECOM Company
Port Tampa Bay	Reliant Energy Charitable Foundation	Irvin Saltzman	Lynda & Richard Sirota	Sutter Health Sacramento Sierra Region	Title Associates
The Portmann Family Charitable Fund	Republic National Distributing Company, LLC	Sharon & Larry Saltzman	Skadden Arps Slate Meagher & Flom LLP	SW Challenge	TJX Companies, Inc.
Powell Industries	James Resnick	Sam's Club	Skanska USA Building, Inc.	Elizabeth & Michael Sweeney	TM Crowley & Associates
Power Services, Inc.	Rhodes Computer Services	Samuel J. Cantor Foundation	Skoloff & Wolfe P.C.	Lisa Marie Sylvia and Mark L. Heleen	Alfred Tobin
Preferred Health Professionals	Jeff Rich—Plum Tree Partners	San Jose Earthquakes Community Fund	The Sleep Family	SYNNEX Corporation	Trayer's Troops
Presidio	Richard M. Powell Foundation	San Manuel Band of Mission Indians	Slice of Lime Foundation	Sysmex America, Inc.	Trident Case
Monika & John W. Preston	Michael J. Richman	San Par Golf Tournament	Phyllis & Douglas A. Smith	Take a Swim Against Cancer-Bucks County Aquatic Swim Teams	Trion Group, Inc.
Pretty Sweet Bake Sale	Cynthia & Steven Rigby	Sanofi-Aventis U.S. LLC 	SMW Trading Company, Inc.	Tap Out Cancer, Inc.	Angela & Gary Trovato
The Prince Henry Charitable Foundation and Dan Anglin	John Rigney	SAP America, Inc.	So Long to Leukemia	TCDI	True North Family Foundation
PRGX USA, Inc.	RMD Corporation—Hooters	SAP NS2/Carahsoft	Solstice Benefits, Inc.	TD Bank	truenorth
Price Chopper Supermarkets	The Robert H. Lyon Leukemia Foundation	Vivian Sasaki	Southeast Nebraska Cancer Center	Team Annie Rose Foundation	Trust Company of the South
Linda & Dr. Steve Priddy	Ruth Robinson	Mr. & Mrs. Richard Schmeelk	Span-America Medical Systems	Team Chad Foundation	Jane & Robert Tschudy
Priority Physicians	The Roderick Seward, Flossie Radcliffe & Helen M. Galloway Foundation	Scott Schweighauser	Paul Sparks	Team Graham, Inc.	Tube City IMS
Proof of the Pudding	Rogers Family Foundation	Barbara Scotti & Ronald Duval	Mark & Carol Spisak	Telstra Global	Renee Twersky
The Pumping Station	Lynn & Peter Rogers	Sedano's Supermarkets	SproutLoud Media Networks, LLC	Teneo Strategy	Michael Twyman
Quintiles	Victoria Rogers	Sempra Employee Giving Network	SRA International	Lee Tepper & Dorine Real	UBS Financial Services
Rabobank		Sempra Energy Foundation	St. Luke's Mountain States Tumor Institute	Terumo BCT	UNC Rex Healthcare
Rahr Malting Co.		Sereno Group Real Estate	The Stanford C. and Mary Claire Finney Foundation	Texas Children's Hospital	Union First Market Bank
Hunter from The Rainbow Bridge		ServiceSource			United Cancer Research Society
					United States Marine, Inc.
					United Way of Wyoming Valley

University of Arizona Medical Center
 University of California, Irvine -UCI
 The University of Chicago Medicine
 University of Kansas Cancer Center
 The University of Pennsylvania - Abramson Cancer Center
 Valenti Mid-Atlantic Management, LLC
 Larry E. Vandiver
 Vanguard Charitable Endowment Program
 Philip J. Venables
 Venari Resources
 Katy Vickery
 The Victor E. & Caroline E. Schutte Foundation - 1959
 Vinson & Elkins LLP
 ViON
 Virginia Tech FarmHouse Fraternity
 Vocera Communications
 Volkert, Inc.
 VyStar Credit Union
 The W. O'Neil Foundation, Inc.
 WalMart
 John and Dee Walsh
 Warner Pacific
 Warren Brown Family Foundation
 Washington Gas
 The Washington Redskins
 Waste Connections, Inc.
 Watkins Meegan LLC
 Watson Wise Foundation
 Wawanesa Insurance
 WBIG
 WebMD

Mark G. Weinstein
 Welden Service & Repair
 The Weiler Foundation
 Shari & Marc Weissbach
 Wellmark Blue Cross & Blue Shield of Iowa
 Wells Fargo Foundation
 Marvin Wenger
 West Marine
 Western Refining, Inc.
 Wet Willie's Management Corp.
 White Castle
 Kenneth Whitney
 Wicker, Smith, O'Hara, McCoy & Ford, P.A.
 Wallace Williams
 Williams-Corbett Foundation
 Willis Auto Campus
 Winnsboro Petroleum Company
 Winston & Strawn LLP
 The Witkoff Group
 WIVB-TV, Channel 4/CW 23
 WMZQ
 Womble Caryle Sandridge & Rice, LLP
 Womble Company, Inc.
 Woodbridge Bowl
 WR Starkey Mortgage, LLP
 WTS, Inc.
 www.lovealwaysfund.org in memory of Emily Schuetz Stryker
 Eric, Tamara and Nicholas Yollick
 Yvonne & Tamer Youssef
 Cathy & Scott Zeilinger
 Ziolkowski Patent Solutions Group
 Joseph Zvesper
 Anonymous (23)

TOP CAMPAIGN FUNDRAISERS

Schools that have raised more than \$25,000, individuals who have raised more than \$50,000 or companies/teams that have raised more than \$100,000 to support LLS's mission.

Laurie Adami & Laurie's Warriors
 Chasity Adkisson
 ADP
 Anjou Ahlborn
 Yvette A. Aleman, P.E.
 Alex and Ani
 Brian Allain
 Timothy Allen
 David Altman
 Vivian Altman
 Elena Alvarez, MD
 Jim A. Anderson, Jr.
 Charles Arnold
 Ren Arrogante
 Astellas USA Foundation
 Austaco, LTD
 Damian Bailey
 Jamie Baker
 Baker Botts L.L.P.
 Baptist Health South Florida
 Barclays
 Christopher Barnes
 Mark Barsotti
 BDO
 Dr. Matthew Beldner - Team Beldner
 Jim Beltz
 Ashlee Berard & Team Never Give Up
 Dr. Gregiore Bergier
 Rose Bevilacqua
 Katie Biehl
 The Blackstone Group
 Brad Blumenfeld
 BMC
 Bianca Bonadelle
 Suzanne Bourque

Julie Boyd
 Jill Broering
 James Brandell
 Bristol-Meyers Squibb Company
 Abbey Brockman
 Jennifer Buffo
 Burlington
 CA Technologies
 Matthew Campbell
 Cancer Treatment Centers of America
 Robert "Spider" Cantley
 Michael Caputo
 Susan Caron
 Donald L. Carter, Jr.
 Carter's Inc.
 Jessica Catlin
 Celgene Corporation
 Deborah Christine
 Brenda Cioce
 Ryan J. Claxton
 Whitney Cohn
 Amy Cohen & Team Amy
 Steve Collins
 Colton's Army
 Derek Copeland
 Catherine Courage
 Dr. Ed Crane
 Crenshaw Team
 Nathan M. Crowley
 Randy Cubriel
 Dr. Jennifer Cultrera
 Lyndsey Danberry
 John Daylor
 Missy Deer
 Chrissy Delisle
 Deloitte
 Chad De Luca
 Gary DePreta
 Joseph DeSabia
 Erin Devlin
 Amy Diaz
 Dr. Larry's Team
 Tam Driscoll
 Andria Duff

Maria Dunleavy
 Eric Eissenstat
 Elbit Systems of America
 Vince Ellison
 Hakan Erdinc
 Ernst & Young LLP
 Alecko Eskandarian
 EZCorp
 Brad Faigle
 Nima Fallahi
 Dr. Julie Fecht
 Michelle Fee
 Barbara Ferris
 Curtis Fong
 Dr. Rafael Fonseca
 The Zack Forbush Family
 Foundation Beyond Belief
 Jeremy Frazier
 Seth Funt
 Jarrod Gans - Team Moda
 The GBAC honored Hero Team
 GEICO
 Genentech/Biogen Idec
 Georgia Chain Gang
 Georgia Pest Control Association
 Dr. Christos Giannoulis†
 Eric Gilseth
 Shelly Glenn
 Global Franchise Group
 James Glover
 Go Mitch Go
 Goldman Sachs
 Thomas Goodmanson
 Google
 Sam Governale
 Jamie Graham
 Great American Cookies
 The Greene Team
 Brittan Griffith
 Nina Gutierrez-Garcia
 Brianna Haag
 Samantha Hale
 Neal Hargrave
 Talin Hartounian
 Chuck Hauff

Susan Hausler
 Jaclyn Herbst
 Courtney Hermann & Fight 2 Win
 Toni Hill
 Ellen Hoffman - Ellen's Angels
 Julie Hopkins
 Marc Hopkins
 Vince Hopkins
 Gordon Huether
 John Hyland
 IHOP
 Incyte Corporation
 Jason's Deli
 Shellee Jenkins
 Patrick Jessee
 Ben Johnshoy
 Charlie Jones
 James P. Joseph, Esq. - Team We Strive
 Michael P. Judge
 Jessica Jung
 Redmond (Roy) Keating - Team Bernie
 John Kellenyi
 Brigid Kelly
 Ricky Kerrigan
 Dana Kettmann
 Kiven, Kotler, Lieberman, Fox, Goldschmidt & Kepes
 Aaron Klosterman
 Dr. Bill Kortesis
 KPMG LLP
 The Kailie Krew
 Kroger Company of Michigan
 Niccole & Jeremy Kroll
 Ryan LaFontaine††
 Christian Langwasser
 Libby Lassiter
 James Lau
 Amanda Leonardo
 Cheryl Levanduski
 Brian Lipstein
 Tim Lowe
 The Lymphomaniacs
 Erin Maggi

DONORS (continued)

MaggieMoo's Ice Cream & Treatery	Nadder Nejad	Ryan Plantz - Team Insure A Cure	Rick Schuerger	Hasti Taghi	United for the Cure
Lucky Malhi	Jennifer Nelson Williams	Lynn Polizos	Scott Schweighauser	Team Blumenfeld & Waterman	Jim Verdi - Team Hardcore for a Cure
Gina Manos	Grace Ng	Pretzelmaker	Zachary Scott	Team Carl	Vistar
Marble Slab Creamery	Kae Lynne Nielson	Dr. Matthew Priddy	Liz Sczudlo & Team Two Sisters	Team Dezma	VITAS Innovative Hospice Care
Suzanne Marse Bourque	Eric North	Larry Provo	Joel Seleskie	Team Doug - Lois Kroll	Waddell & Reed
Nicholas Mastroianni, III	Linda Norton	Jason Putorti	Tom Sessi	Team Gary	Walgreens
Ryan McArdle	Blair Nottingham	PVH	Nikolas Sgagias	Team Honored Hero	Vanessa Walker
Brenda McCarthy	Novartis Pharmaceuticals Corporation	PwC	Neal Shah	Team Hope	Walt Whitman High School
Dan McCarthy	Adam Noyes SVP of Proof of the Pudding's Hospitality for Hope Campaign	John Ragan	Kris Shanahan	Team Hunter	Walter Johnson High School
Kathy McCauslin-Cadieux	Lynne O'Brien	Rampart High School	David Shapiro	Team Jay	Karen Warner
Danny McGeady	Todd Oakes	Greg Rankich	Kandice Sheehan Fergus	Team Laura	Washington Gas
Reeves McGee	Jan Ochocki	Gray Reed	JoAnn Shaw	Team LIV	Krystall Waters
Daniel McGhee	Richard Ojeda	Riders of the Storm	Lance Shaw	Team LOL	Watertown Middle School
Kristi McKeown	Onyx Pharmaceuticals, Inc.	Jacob Robinson & Team K.O.	Kandice Sheehan	Team Mickey	Carly Watts
Meghan McWalters	David Osborn	Corey M. Roblee	Sonu Singhvi	Team PhRMA	Wells Fargo
Amber Melby	Gwen Ottenberg	Jennifer Rogers & Robert Carlock	Robert Singley	Team Reese	DebiJo Wheatley
Bobby Menges—Team I Came, I Saw, I Conquered Cancer	Stacie Oxman	Melanie Romanaux	Leah Slocum	Team Ryan	Suzy Whittenton
John Merrill	Mark Pahl - Team (R)Andy	Jose C. Romano	Evelyn Smallwood	Team Skinner - RAAM 2014	Sarah Wilbur
Kimie Metcalf	Michael Parrish	Carrie Ronan	Ashlyn Smith	Team Stephanie	William Mason High School
Lance Meyerowich	Partners For A Cure	Sondra Rose	Dana Smith	Team Stronger Than You Think	Chris Wilno & We Will Find a Cure
Dr. Gabby Meyers - Team OHSU	Justin Paschal	Brewer Rowe	Kyra Smith	Team Today - Dr. Christina Veit & Reina Sinni	Samara Wolpe & the Wolpe Family†
Mike's Cancer Crushers	Alex Perdikis	Benjamin Rubenstein	Blair Smittcamp	Team Virginia	The Womble Bulldogs
Millennium: The Takeda Oncology Company	Elena Peroulakis	Ryan's Light	John Sorrentino	Terumo BCT	
Alton Moore	Mark Peterson	Salesforce.com	Spectrum Pharmaceuticals	Lee Tessier	
Cheryl Mosley	Pfizer Inc.	Dr. Larry Saltzman	Alex Stamas	Teva Oncology	
Gary Moy	Pharmacyclics/Janssen Pharmaceutical Companies	Paula Sanchez	Stater Bros. Charities	Kim Tindall††	
Casey Munck	Justine M. Phillips, Esq.	Tony Sanchez	Nick Stefanakis	Katie Tipper-McWhorter	
Cristina Muñoz	Mandy Pilgrim	SanDisk Corporation	Stewart School	Lona Todd	
NARS	Becca Piluzza	Sarah Cannon Blood Cancer Network	Deirdre Strunk	Mark Torello	
National Capital Area Chapter MWOY Leadership Team		Fuad Sawaya	Glenn Sullivan	Greg Trayer	
		Col. Donald Schaet USMC (retired)	Mary Sullivan	UBS Financial Services, Inc.	
			Rebecca Sweet		

† National Man & Woman of the Year

†† National Man & Woman of the Year All Star Alumni

LEGACY CIRCLE

Legacy Circle honors those who designate LLS as a beneficiary of their will, trust, retirement account or insurance policy, or fund a charitable gift annuity. We list our newest members below along with those whose bequests of \$10,000 or more were received this year.

Jared Brancazio	Ida Daly*	Joyce L. Holl	Jamie Klingman	Mary Jean Neal*	Julie Roth*	Steven W.L. Solana	Estella Ruth Watts*
Barbara Brunell	Kenneth Dawson*	Joseph Ignatowski	Melvin Kraemer*	Annabel Neff*	Angela Ryan*	David and Jeanette Stevens	Beth Weigand
Sandra Backus*	Frederick Dibble*	Edith Ingram*	Wallace Blaine Lawrence*	Jeffrey and Paula Nelson	John Seijun Sato*	William Stockert*	Anonymous (6)
Patrick Bianchi*	Allan Ecker*	William Jackson*	Edward and Alice Leighten*	Alan R. Propst*	Elmo and Dolores Schmid*	Bruce Swartz*	
Thomas Blackman*	Daniel Feldt	Patricia Johnson*	Helen Lippert*	Kyle and Monica Roderick	Norma Scott*	Scott A. Thomas	
Edith Blankenship*	Lawrence and Piera Freitag	Louise B. Judsen*	Janet Martin*	Rose Rodriguez*	Bruno and Irma Selmi*	Diego Tobon*	
Lorie Coon*	Dennis Gerin*	Diane Kalliam	Tim and Jane McKay	Erick Rohde*	Elisabeth Situm*	Elly Susan Valas	
David and Carol Cooper	Charles Gibbs*	Bonnie Kaltenborn*	Jane Metzger*	Winnifred Roman*	Alfred Skeaney*	Sarah Walters*	* Deceased
Joy Cowan	Barbara Gol	Beth Kissling	Rose Morrissey*	Charles Rose*	Georgette Skellenger*		

INDEPENDENT AUDITORS' REPORT

The Board of Directors
The Leukemia & Lymphoma Society, Inc.:

We have audited the accompanying consolidated financial statements of The Leukemia & Lymphoma Society, Inc. (LLS), which comprise the consolidated balance sheet as of June 30, 2014, and the related consolidated statements of activities, functional expenses and cash flows for the year then ended, and the related notes to the consolidated financial statements.

Management's Responsibility for the Financial Statements: Management is responsible for the preparation and fair presentation of these consolidated financial statements in accordance with U.S. generally accepted accounting principles; this includes the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of consolidated financial statements that are free from material misstatement, whether due to fraud or error.

Auditors' Responsibility: Our responsibility is to express an opinion on these consolidated financial statements based on our audit. We conducted our audit in accordance with auditing standards generally accepted in the United States of America. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free from material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the consolidated financial statements. The procedures selected depend on the auditors' judgment, including the assessment of the risks of material misstatement of the consolidated financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the organization's preparation and fair presentation of the consolidated financial statements in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the organization's internal control. Accordingly, we express no such opinion. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

Opinion: In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the financial position of The Leukemia & Lymphoma Society, Inc. as of June 30, 2014, and the changes in its net assets and its cash flows for the year then ended in accordance with U.S. generally accepted accounting principles.

Report on Summarized Comparative Information: We have previously audited LLS's consolidated financial statements, and we expressed an unmodified opinion on those audited consolidated financial statements in our report dated September 18, 2013. In our opinion, the summarized comparative information presented herein as of and for the year ended June 30, 2013 is consistent, in all material respects, with the audited consolidated financial statements from which it has been derived.

KPMG LLP

October 15, 2014

CONSOLIDATED **BALANCE SHEET**

The Leukemia & Lymphoma Society, Inc. / June 30, 2014 (With comparative amounts at June 30, 2013) (In thousands)

	<u>2014</u>	<u>2013</u>
Assets		
Cash and cash equivalents (note 6)	\$ 28,771	27,300
Prepaid expenses and other assets	5,362	5,555
Legacies and contributions receivable, net (note 5)	9,113	8,026
Investments (notes 3 and 6)	188,885	190,555
Fixed assets, net (note 7)	<u>16,604</u>	<u>10,853</u>
Total assets	<u>\$ 248,735</u>	<u>242,289</u>
Liabilities and Net Assets		
Liabilities:		
Accounts payable and accrued expenses	\$ 20,685	21,388
Deferred revenue (note 6)	26,745	35,074
Awards and grants payable (note 2)	84,201	74,825
Co-Pay assistance payable (note 2)	<u>16,698</u>	<u>7,237</u>
Total liabilities	<u>148,329</u>	<u>138,524</u>
Commitments and contingencies (notes 2 and 9)		
Net assets (note 4):		
Unrestricted	68,842	91,217
Temporarily restricted	27,989	9,105
Permanently restricted	<u>3,575</u>	<u>3,443</u>
Total net assets	<u>100,406</u>	<u>103,765</u>
Total liabilities and net assets	<u>\$ 248,735</u>	<u>242,289</u>

See accompanying notes to consolidated financial statements.

CONSOLIDATED STATEMENT OF **ACTIVITIES**

The Leukemia & Lymphoma Society, Inc. / Year ended June 30, 2014 (With summarized totals for the year ended June 30, 2013) (In thousands)

	Unrestricted	Temporarily restricted	Permanently restricted	Total	
				2014	2013
Operating Revenue					
Campaign contributions	\$ 250,433	20,654	—	271,087	276,098
Less direct donor benefit costs	(28,784)	—	—	(28,784)	(35,510)
Net campaign contributions	221,649	20,654	—	242,303	240,588
Co-pay contributions	—	67,100	—	67,100	48,143
Legacies	4,050	1,505	—	5,555	4,226
Donated services and media (note 6)	10,985	—	—	10,985	7,750
Net interest and dividend income	1,365	44	79	1,488	2,075
Net assets released from restrictions:					
Co-pay assistance	55,393	(55,393)	—	—	—
Satisfaction of other donor restrictions	15,239	(15,239)	—	—	—
Total operating revenue	308,681	18,671	79	327,431	302,782
Operating Expenses (note 10)					
<i>Program services:</i>					
Research	85,034	—	—	85,034	76,494
Patient and community service	104,170	—	—	104,170	104,830
Public health education	47,585	—	—	47,585	46,080
Professional education	19,656	—	—	19,656	20,729
Total program services	256,445	—	—	256,445	248,133
<i>Supporting services:</i>					
Management and general	28,734	—	—	28,734	28,009
Fund raising	54,353	—	—	54,353	49,620
Total supporting services	83,087	—	—	83,087	77,629
Total operating expenses	339,532	—	—	339,532	325,762
Change in net assets from operating activities	(30,851)	18,671	79	(12,101)	(22,980)
Write off of contribution receivable (note 5)	(3,507)	—	—	(3,507)	—
Foreign currency translation adjustment	(153)	—	—	(153)	(84)
Net increase in fair value of investments (note 3)	12,136	213	53	12,402	9,689
Change in net assets	(22,375)	18,884	132	(3,359)	(13,375)
Net Assets					
Beginning of year	91,217	9,105	3,443	103,765	117,140
End of year	\$ 68,842	27,989	3,575	100,406	103,765

See accompanying notes to consolidated financial statements.

CONSOLIDATED STATEMENT OF FUNCTIONAL EXPENSES


The Leukemia & Lymphoma Society, Inc. / Year ended June 30, 2014 (With comparative totals for the year ended June 30, 2013) (In thousands)

	Program Services					Supporting Services			Total		Direct Donor Benefit Costs	
	Research	Patient and community service	Public health education	Professional education	Total	Management and general	Fund raising	Total	2014	2013	2014	2013
	Awards and grants (note 2)	\$ 63,716	—	—	—	63,716	—	—	—	63,716	57,055	—
Therapy acceleration program (note 2)	16,107	—	—	—	16,107	—	—	—	16,107	14,912	—	—
Financial aid to patients	—	2,524	—	—	2,524	—	—	—	2,524	2,989	—	—
Co-pay assistance (note 2)	—	49,246	—	—	49,246	—	—	—	49,246	42,650	—	—
Co-pay processing fees	67	1,159	748	329	2,303	755	1,509	2,264	4,567	4,599	—	—
Donated services and media (note 6)	1,128	3,858	600	—	5,586	—	5,399	5,399	10,985	7,750	—	—
Salaries	2,591	23,024	20,471	7,451	53,537	10,315	13,705	24,020	77,557	73,495	—	—
Employee benefits and taxes (note 8)	173	5,285	4,920	3,341	13,719	3,420	3,996	7,416	21,135	21,432	—	—
Temporary services	97	1,667	1,075	473	3,312	1,086	2,170	3,256	6,568	4,923	—	—
Occupancy (note 10)	23	2,817	2,293	940	6,073	1,396	1,635	3,031	9,104	9,332	—	—
Insurance	2	151	134	148	435	109	130	239	674	678	—	—
Telephone	8	665	725	617	2,015	475	795	1,270	3,285	3,438	—	—
Travel	124	1,728	1,385	469	3,706	719	1,054	1,773	5,479	4,530	4,432	8,083
Printing, advertising, and supplies	49	2,082	4,968	1,864	8,963	3,307	9,945	13,252	22,215	25,400	5,017	5,641
Equipment rentals and maintenance	2	795	696	626	2,119	551	606	1,157	3,276	2,635	—	—
Postage and shipping	2	873	2,989	127	3,991	989	3,685	4,674	8,665	10,226	—	—
Meetings	602	882	1,307	262	3,053	300	763	1,063	4,116	4,657	11,179	11,989
Professional fees	340	5,866	3,783	1,666	11,655	3,819	7,635	11,454	23,109	29,005	1,741	2,562
Miscellaneous	1	1,043	640	292	1,976	737	502	1,239	3,215	3,006	6,415	7,235
Depreciation and amortization	2	505	851	1,051	2,409	756	824	1,580	3,989	3,050	—	—
Total expenses	\$ 85,034	104,170	47,585	19,656	256,445	28,734	54,353	83,087	339,532	325,762	28,784	35,510

See accompanying notes to consolidated financial statements.

EXPENSES

Research	25.0%
Patient and Community Service	30.7%
Public Health Education	14.0%
Professional Education	5.8%
Total Program Services	75.5%
Management and General	8.5%
Fund raising	16.0%
Total Supporting Services	24.5%
Total Expenses	100.0%



CONSOLIDATED STATEMENT OF CASH FLOWS

The Leukemia & Lymphoma Society, Inc. / Year ended June 30, 2014 (With comparative amounts for the year ended June 30, 2013) (In thousands)

	2014	2013
Cash flows from operating activities:		
Change in net assets	\$ (3,359)	(13,375)
Adjustments to reconcile change in net assets to net cash (used in) provided by operating activities:		
Net increase in fair value of investments	(12,402)	(9,689)
Depreciation and amortization	3,989	3,050
Provision for uncollectible accounts	(304)	14
Changes in operating assets and liabilities:		
Prepaid expenses and other assets	193	1,161
Legacies and contributions receivable	(783)	(2,627)
Accounts payable and accrued expenses	(703)	1,192
Deferred revenue	(8,329)	17,337
Awards and grants payable	9,376	6,510
Co-Pay assistance payable	9,461	1,586
Net cash (used in) provided by operating activities	<u>(2,861)</u>	<u>5,159</u>
Cash flows from investing activities:		
Purchases of fixed assets	(9,740)	(7,049)
Purchases of investments	(77,132)	(54,862)
Sales of investments	91,204	58,080
Net cash provided by (used in) investing activities	<u>4,332</u>	<u>(3,831)</u>
Net increase in cash and cash equivalents	1,471	1,328
Cash and cash equivalents at beginning of year	27,300	25,972
Cash and cash equivalents at end of year	<u>\$ 28,771</u>	<u>27,300</u>

See accompanying notes to consolidated financial statements.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

The Leukemia & Lymphoma Society, Inc. / June 30, 2014 (With comparative amounts as of and for the year ended June 30, 2013)

1. Organization and Summary of Significant Accounting Policies

Organization

The Leukemia & Lymphoma Society, Inc. (LLS) is the world's largest voluntary health agency dedicated to finding cures for blood cancers. LLS's mission is to cure leukemia, lymphoma, Hodgkin's disease, and myeloma and improve the quality of life of patients and their families. LLS research grants have funded many of today's most promising advances for the treatment of blood cancer patients, including targeted therapies and immunotherapies. LLS is a leading source of publicly available information for blood cancer, education and support, and influences policies that accelerate the development and approval of new blood cancer therapies. LLS advocates for blood cancer patients and their families, helping patients navigate their cancer treatments and ensuring they have access to quality, affordable and coordinated care. LLS is dedicated to removing barriers to care by representing the healthcare and medical research interests of patients and families to policymakers at all levels of government.

Tax-Exempt Status

LLS qualifies as a charitable organization as defined by Internal Revenue Code Section 501(c)(3) and, accordingly, is exempt from federal income taxes under Internal Revenue Code Section 501(a). Additionally, since LLS is publicly supported, contributions to LLS qualify for the maximum charitable contribution deduction under the Internal Revenue Code.

The Leukemia & Lymphoma Society of Canada, Inc. (LLSC) is registered as a charitable organization under the Income Tax Act (Canada) and is, therefore, not subject to income taxes if certain disbursement requirements are met.

LLS recognizes the effect of income tax positions only if those tax positions are more likely than not to be sustained. Income generated from activities unrelated to LLS's exempt purpose is subject to tax under Internal Revenue Code Section 511. LLS did not recognize any unrelated business income tax liability for the years ended June 30, 2014 and 2013.

Principles of Consolidation

The accompanying consolidated financial statements include the accounts of LLS, which encompasses the National Office of LLS and its fifty-four chapters in the United States, and LLS's not for profit affiliates, LLSC and its five chapters in Canada, The Leukemia & Lymphoma Society Research Programs, Inc., and The Leukemia & Lymphoma Society Research Foundation. All significant intercompany and intra-LLS accounts and transactions have been eliminated in consolidation.

Estimates

The preparation of the consolidated financial statements in conformity with generally accepted accounting principles requires LLS's management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. The significant estimates made in the preparation of these consolidated financial statements include the fair value of alternative investments, the allowance for uncollectible accounts, the allocation of expenses, and the valuation of donated services and media. Actual results could differ from those estimates.

Risks and Uncertainties

LLS invests in various investment securities. Investment securities are exposed to various risks such as interest rate risks, fluctuations in market values, and credit risks. Due to the level of risk associated with certain investment securities, it is at least reasonably possible that changes in the values of investment securities will occur in the near term and that such changes could materially affect the amounts reported in the consolidated balance sheet.

LLS's principal source of revenue is amounts contributed by the general public. Accordingly, LLS's operations are impacted by individual contributions, which are impacted by general economic conditions, employment levels, and other factors over which LLS has little or no control. By contrast to the granularity of the general public donations, the co-pay program in 2014 and 2013 was funded by six and five donors, respectively.

Summarized Financial Information

The consolidated financial statements are presented with 2013 summarized or comparative information. With respect to the consolidated statement of activities, such prior year information is not presented by net asset class and, in the consolidated statement of functional expenses, 2013 expenses by object are presented in total rather than by functional category. Accordingly, such information should be read in conjunction with LLS's 2013 consolidated financial statements from which the summarized information was derived.

Subsequent Events

LLS evaluated subsequent events after the balance sheet date of June 30, 2014 through October 15, 2014, which was the date the consolidated financial statements were issued, and concluded that no additional disclosures are required.

Net Asset Classifications

To ensure observance of limitations and restrictions placed on the use of resources available to LLS, funds that have similar characteristics have been classified into three net asset categories as follows:

Unrestricted net assets: Consist of funds that are fully available, at the discretion of LLS's Board of Directors, for LLS to utilize in any of its programs or supporting services.

Temporarily restricted net assets: Consist of funds that are restricted by donors for a specific time period and/or purpose.

Permanently restricted net assets: Consist of funds that contain donor imposed restrictions requiring that the principal be invested in perpetuity. Income earned on these funds are recorded as temporarily restricted net assets and are released from restriction when the donor stipulated purpose has been fulfilled and/or the amount has been appropriated in compliance with the Board-approved spending policy (note 4).

Foreign Currency Translation

LLSC uses the Canadian dollar as its functional currency. Accordingly, the currency impact of the translation of the financial statements of LLSC to U.S. dollars is included as a translation adjustment in the consolidated statement of activities.

Fair Value Measurements

Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants at the measurement date. The three levels of the fair value hierarchy are as follows:

Level 1 inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities that a reporting entity has the ability to access at the measurement date.

Level 2 inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly.

Level 3 unobservable inputs for the asset or liability.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

The Leukemia & Lymphoma Society, Inc. / June 30, 2014 (With comparative amounts as of and for the year ended June 30, 2013)

LLS follows the provisions of Accounting Standards Codification (ASC) 820, *Fair Value Measurement*, for its alternative investments that do not have readily determinable fair values, including hedge funds, limited partnerships, and other funds. This guidance allows, as a practical expedient, for the estimation of the fair value of investments in investment companies for which the investment does not have a readily determinable fair value, using net asset value per share or its equivalent, as reported by the investment managers.

Most investments classified in Levels 2 and 3 consist of shares or units in investment funds as opposed to direct interests in the funds' underlying holdings, which may be marketable. Because the net asset value reported by each fund is used as a practical expedient to estimate the fair value of LLS's interest therein, its classification in Level 2 or 3 is based on LLS's ability to redeem its interest at or near June 30. If the interest can be redeemed in the near term, the investment is classified as Level 2. The classification of investments in the fair value hierarchy is not necessarily an indication of the risks, liquidity, or degree of difficulty in estimating the fair value of each investment's underlying assets and liabilities.

The carrying value of cash and cash equivalents, accounts payable and accrued expenses, and grants payable approximates fair value because of their short-term nature.

Contributions, Grants and Deferred Revenue

Contributions are recorded as revenue, at their fair value, when received or promised unconditionally. Contributions received with donor restrictions that limit their use are reported as either temporarily or permanently restricted revenue. When a donor restriction is met through the passage of time or fulfillment of a purpose restriction, temporarily restricted net assets are reclassified to unrestricted net assets and reported in the consolidated statement of activities as net assets released from restrictions. Conditional contributions are recognized as revenue when the conditions have been substantially met. Certain grants are accounted for as exchange transactions whereby revenue is recognized when the related expenses are incurred. Amounts received under these arrangements but not yet expended are reported as deferred revenue.

Donated Services

LLS has determined that certain of the donated services it receives meet the criteria for recognition in the consolidated financial statements. The value of contributed services was determined for volunteers that possess specialized skills, and would otherwise need to be purchased. These services are recognized as revenue and expense.

Donated Media

LLS has conducted national public service announcements (PSA) media campaigns and benefited from donated media time that was aired on television and radio. The value of contributed media, which is recognized in the financial statements, was estimated based on the placement, audience, and demographics of the PSA's.

Cash Equivalents

Cash equivalents consist of short-term investments with an original maturity of three months or less from date of purchase, except for amounts held in investments.

Investments

Investments are stated at fair value based upon quoted market prices, except for the fair values of alternative investments which are based on net asset values provided by the fund managers or general partners, based upon the underlying net assets of the funds consistent with the concepts of ASC 820. These values are reviewed and evaluated by management.

Fixed Assets and Depreciation

Fixed assets, which consist principally of equipment, software, and leasehold improvements, are

recorded at cost, and are depreciated or amortized using the straight-line method over the estimated useful lives of the assets or the terms of the leases, if shorter, ranging 2 to 10 years (leasehold improvements 7 years; furniture, fixtures, and office equipment 7 to 10 years, and computer equipment and software 2 to 5 years).

Professional Fees

Professional fees included in the consolidated financial statements principally include professional fund-raising fees, contracted software development, and legal and auditing fees.

Reclassifications

Certain reclassifications of 2013 amounts have been made to conform to the 2014 presentation.

2. Research and Co-Pay Assistance Program

LLS has various activities that are utilized to carry out its mission as presented below:

Research:

Awards and Grants: Awards and grants for research are approved by LLS's Board of Directors and are recognized as expense when contractual conditions have been satisfied. The budgets for multi-year grants, which are generally two to five years in length, are approved on an annual basis and may be terminated at the discretion of LLS's Board of Directors. LLS has multi-year grant commitments of \$67,590,000 at June 30, 2014 which are conditioned upon future events and, accordingly, are not recorded. LLS has unconditional grants payable of \$84,201,000 and \$74,825,000 at June 30, 2014 and 2013, respectively, which are anticipated to be paid in the next year. Grant refunds of approximately \$821,000 and \$1,844,000 as of June 30, 2014 and 2013, respectively, have been netted against awards and grants expense.

Therapy Acceleration Program (TAP): TAP is LLS's strategic initiative to speed the development of blood-cancer treatments and supportive diagnostics by creating business alliances with biotechnology and pharmaceutical companies. TAP provides funding for investigational new drug-enabling studies and clinical-stage projects. TAP contracts are recognized as an expense in the year program milestones are achieved. Multi-year contracts, which are generally two to three years in length, are reviewed against milestones on a quarterly basis and may be terminated at the discretion of LLS's Board of Directors. LLS has contract commitments of \$28,575,000 and \$40,964,000 at June 30, 2014 and 2013, respectively, that are conditioned upon future events and, accordingly, are not recorded.

Commitments for the awards and grants and TAP programs are contingent upon the satisfactory completion of milestones and/or other conditions in the grant and contract agreements. If such conditions are satisfied, the amounts are estimated to be paid as follows (in thousands):	Year ending June 30:	
	2015	\$ 50,448
	2016	30,765
	2017	12,268
	2018 and thereafter	<u>2,684</u>
	Total	<u>\$ 96,165</u>

Co-Pay Assistance Program:

Co-Pay Assistance Program: The Co-Pay Assistance program offers financial assistance to patients in meeting their insurance co-pay obligations for prescription medications or private/public health insurance premiums. Amounts awarded under the program are expensed in the year approved based on the available funding in the program. Revenue is recognized when the grants are received while expenses are recognized as patients are approved for participation according to program criteria. Accordingly, LLS has recognized \$11,707,000 in temporarily restricted revenue in the current year for which the corresponding expense will not be recognized until the subsequent fiscal year as patients are approved in the program. The Co-Pay Assistance payable of \$16,698,000 and \$7,237,000 has

been established based on approved patient applications received through June 30, 2014 and 2013, respectively. At June 30, 2014, temporarily restricted net assets include \$11,707,000 received in 2014 which are available for expenditure and are intended to be awarded in fiscal 2015.

The following summarizes the activities of the Co-Pay Assistance program in 2014 and 2013.

	2014	2013
Grant commitments	\$ 67,100	48,143
Amount expended during the year:		
Direct assistance to patients	(49,246)	(42,650)
Other expenses incurred and reimbursed under the contract	(6,147)	(5,493)
Amounts available for expenditures in the next year	<u>\$ 11,707</u>	<u>—</u>

3. Investments

The following tables present LLS's fair value hierarchy of investments measured at fair value on an annual basis as of June 30, 2014 and 2013 (in thousands):

	2014	Level 1	Level 2	Level 3
Money market funds and cash	\$25,633	25,633	—	—
Fixed income:				
Long duration fixed income (mutual fund)	55,513	55,513	—	—
Short duration fixed income (mutual fund)	33,923	33,923	—	—
U.S. Treasury Inflation-Protected Security fund (TIPS) and other	3,431	1,057	2,374	—
Equities:				
Large cap equity	5,594	5,594	—	—
International equity	6,905	6,905	—	—
Small/mid cap equity	1,717	1,717	—	—
Alternative investments:				
Multistrategy hedge funds	40,769	—	40,769	—
Long/short equities	3,705	—	—	3,705
Real assets	8,826	—	8,826	—
Limited partnership equity indices	2,869	—	2,869	—
	<u>\$188,885</u>	<u>130,342</u>	<u>54,838</u>	<u>3,705</u>

	2013	Level 1	Level 2	Level 3
Money market funds and cash	\$ 1,071	1,071	—	—
Fixed income:				
Long duration fixed income (mutual fund)	63,003	63,003	—	—
Short duration fixed income (mutual fund)	32,316	32,316	—	—
U.S. Treasury Inflation-Protected Security fund (TIPS) and other	3,231	940	2,291	—

Equities:

Large cap equity	6,901	6,901	—	—
International equity	9,739	9,739	—	—
Small/mid cap equity	2,022	2,022	—	—

Alternative investments:

Multistrategy hedge funds	58,323	—	58,323	—
Long/short equities	3,358	—	—	3,358
Real assets	7,855	—	7,855	—
Limited partnership equity indices	2,736	—	2,736	—
	<u>\$190,555</u>	<u>115,992</u>	<u>71,205</u>	<u>3,358</u>

Investment expenses of \$1,338,000 and \$1,301,000 have been netted against the net increase in fair value of investments for the years ended June 30, 2014 and 2013, respectively. The unrealized gains were \$6,573,000 and \$3,810,000 for the years ended June 30, 2014 and 2013, respectively.

LLS's alternative investments are diversified across four investment strategies, as follows:

1. *Multi strategy hedge funds* – represent investments in a broad range of investment strategies that seek to exploit opportunities as they occur in the markets due to temporary dislocations or structural inefficiencies and include event-driven strategies, distressed debt, merger and other arbitrage, and value investing.
2. *Long/short equities* – primarily investments in funds that, in turn, invest in liquid, marketable securities, attempting to realize gains through the identification of mispriced securities.
3. *Real asset strategy* – passively managed real asset portfolios comprise Real Estate Investment Trust Index, commodities, and global natural resource stocks.
4. *Limited partnership equity indices* – The underlying holdings of the limited partnership equity indices are principally domestic and international marketable securities.

These strategies create indirect exposure to LLS through short sales of securities, trading in future and forward contracts, and other derivative products. Derivatives are investment contracts used to hedge risk. While these financial instruments may contain varying degrees of risk, LLS's risk with respect to such transactions is limited to its capital balance in each investment.

	Redemption period	Amount
LLS's alternative investments contain various redemption restrictions with required written notice ranging from 1 to 95 days. By contrast, all of LLS's nonalternative investments are highly liquid and can be redeemed daily without restriction. As of June 30, 2014, the following table summarizes the composition of such alternative investments at fair value by the various redemption provisions (in thousands):	Daily	\$ 8,826
	Monthly	2,869
	Quarterly	40,769
	Annual	3,705
	Total	<u>\$ 56,169</u>

As of June 30, 2014 and 2013, LLS has no unfunded commitments on its alternative investments.

The following table presents a reconciliation for all Level 3 assets measured at fair value as of June 30, 2014 and 2013 (in thousands):

	Level 3 Assets	
	2014	2013
Balance at July 1	\$ 3,358	3,042
Investment expense	(79)	(79)
Net increase in fair value	426	395
Balance at June 30	<u>\$ 3,705</u>	<u>3,358</u>

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

The Leukemia & Lymphoma Society, Inc. / June 30, 2014 (With comparative amounts as of and for the year ended June 30, 2013)

4. Temporarily and Permanently Restricted Net Assets

Temporarily restricted net assets and the income earned on permanently restricted net assets are available for the following purposes at June 30, 2014 and 2013 (in thousands):

	2014		2013	
	Temporarily restricted	Permanently restricted	Temporarily restricted	Permanently restricted
Time restrictions	\$ 1,295	-	992	-
Research	10,724	3,270	5,721	3,201
Patient service	2,802	-	2,126	-
Co-pay assistance	11,707	-	-	-
Other	1,461	305	266	242
Total	<u>\$ 27,989</u>	<u>3,575</u>	<u>9,105</u>	<u>3,443</u>

LLS follows the provisions of the New York Prudent Management of Institutional Funds Act (NYPMIFA), which imposes guidelines on the management and investment of endowment funds. LLS has interpreted the relevant law as allowing LLS to appropriate for expenditure or accumulate so much of an endowment fund as LLS determines is prudent considering the uses, benefits, purposes, and duration for which the endowment fund is established, subject to the intent of the donor as expressed in the gift instrument.

LLS has adopted investment and spending policies for endowment assets that attempt to provide a predictable stream of funding to programs supported by its endowment funds while seeking to protect the original value of the gift. The spending rate policy at June 30, 2014 and 2013 was 4%, plus any additional amounts advised by donors. Under this policy, the endowment assets are invested in a manner that is intended to produce results consistent with LLS's overall investment strategy.

The following table presents changes in the donor-restricted endowment funds for the year ended June 30, 2014 and June 30, 2013 (in thousands):

	2014			2013		
	Temporarily restricted	Permanently restricted	Total	Temporarily restricted	Permanently restricted	Total
Endowment net assets at July 1	\$ 3,122	3,443	6,565	\$ 3,155	3,357	6,512
Investment income	44	79	123	64	26	90
Net appreciation	213	53	266	353	60	413
Appropriation for expenditure	(215)	-	(215)	(450)	-	(450)
Endowment net assets at June 30	<u>\$ 3,164</u>	<u>3,575</u>	<u>6,739</u>	<u>\$ 3,122</u>	<u>3,443</u>	<u>6,565</u>

5. Legacies and Contributions Receivable

LLS's legacies and contributions receivable at June 30, 2014 and 2013 consist of unconditional promises to give and legacies for which the underlying wills have been declared valid by the probate court and no other conditions are required to be met. Contributions receivables are originally recorded based on discounted cash flows using a risk adjusted discount rate which is considered a Level 3 input in the fair value hierarchy. Amounts are scheduled to be received as follows (in thousands):

	2014	2013
Less than one year	\$ 5,301	4,733
1 to 5 years	4,137	4,130
After 5 years	650	600
Subtotal	10,088	9,463
Less:		
Allowance for uncollectible accounts	(488)	(792)
Discount to present value (1.5% to 5.0%)	(487)	(645)
Total	<u>\$ 9,113</u>	<u>8,026</u>

In 2014, a foundation notified LLS that it intended to cancel a grant commitment that was made in the previous year due to a change in the foundation's objectives. Accordingly, LLS wrote off the balance of the contribution receivable in the amount of \$3,507,000.

6. Deferred Revenue, Donated Services and Media

During 2013, LLS received a \$20,000,000 grant with the contractual agreement to be utilized on research which is jointly identified by the grantor and LLS. At June 30, 2014 and 2013, these funds were held equally between cash and investments. Revenue under this grant is expected to be recognized over the next three years, as expenses are incurred. At June 30, 2014 and 2013, the unexpended balance of the grant of \$13,700,000 and \$19,500,000, respectively, are included in deferred revenue. The remaining balance of deferred revenue includes amounts received for special events that will be held subsequent to the fiscal year-end.

The value of donated services for family support group facilitators and research grant reviewers, as well as donated media are included in both revenue and expense as shown below (in thousands):

	2014	2013
Donated services	\$ 4,985	5,492
Donated media	6,000	2,258
Total	<u>\$ 10,985</u>	<u>7,750</u>

7. Fixed Assets, Net

Fixed assets at June 30, 2014 and 2013 consist of the following (in thousands):

	2014	2013
Leasehold improvements	\$ 1,135	1,043
Furniture, fixtures, and other office equipment	2,646	2,626
Computer equipment and software	27,913	18,432
Total	\$ 31,694	22,101
Less accumulated depreciation and amortization	(15,090)	(11,248)
Fixed assets, net	<u>\$ 16,604</u>	<u>10,853</u>

8. Retirement Plans

LLS has a defined contribution 403(b) pension plan covering all employees meeting age and service requirements. Contributions are based on a percentage of each eligible employee's salary and years of service. Expenses under this plan aggregated \$4,214,000 and \$4,173,000 for the years ended June 30, 2014 and 2013, respectively.

LLS has 457(b) deferred compensation plans (the 457 Plans) for its executive staff. The 457 Plans are nonqualified deferred compensation plans subject to the provisions of the Internal Revenue Code Section 457. Expenses under the 457 Plans approximated \$296,000 and \$195,000 for the years ended June 30, 2014 and 2013, respectively. The assets and liabilities of the 457 Plans are included in investments and accounts payable and accrued expenses in the accompanying consolidated balance sheet and amounted to approximately \$1,589,000 and \$1,357,000 at June 30, 2014 and 2013, respectively.

9. Lease Commitments

The leases for premises, which LLS's National Office and chapters occupy, expire on various dates through September 30, 2023 and provide for certain payments subject to escalation and periodic rate increases relating to real estate taxes, operating expenses, and utilities.

The approximate minimum aggregate future annual rental commitments are summarized as follows (in thousands):

Year ending June 30:

2015	\$ 8,010
2016	6,477
2017	3,826
2018	2,349
2019	1,258
2020 and thereafter	3,823
Total	\$ 25,743

10. Joint Costs Allocation

For the years ended June 30, 2014 and 2013, LLS incurred expenses to conduct activities that had both fundraising appeals as well as mission program and management and general components (joint activities). Those joint activities included direct mail, coinboards, and media campaigns. Such costs are allocated based on applicable accounting standards and were allocated as follows (in thousands):

	2014	2013
Fund raising	\$ 12,645	10,577
Patient and community service	1,513	1,895
Public health education	8,456	8,966
Total	\$ 22,614	21,438

NATIONAL LEADERS

Chairman of the Board
Timothy S. Durst, JD
Baker Botts LLP
Dallas, TX

Vice Chair
James H. Davis, PhD, JD
Highland, MD

Secretary/Treasurer
Kenneth M. Schwartz
Ernst & Young, LLP
New York, NY

Jorge L. Benitez
Coral Gables, FL

James "Jay" E. Bradner, MD
Dana-Farber Cancer Institute
Boston, MA

Peter Bennett Brock
Brock Development Corp.
Palm Beach Gardens, FL

A. Dana Callow, Jr.
Boston Millennia Partners
Boston, MA

Scott A. Carroll
Jackson Lewis
Cincinnati, OH

Elizabeth Clark, PhD, MPH, ACSW
Rockville, MD

Graciela C. Eleta
Eleta Consulting, Inc.
Guaynabo, PR

Bernard H. Garil
Delray Beach, FL

Beth E. Hawley
Cogent HMG
Wayne, PA

Pamela J. Haylock
Medina, TX

Raanan Horowitz
Elbit Systems of America, LLC
Fort Worth, TX

Richard M. Jeanneret
Ernst & Young, LLP
New York, NY

Joseph B. Kelley
Lilly USA, LLC
Washington, DC

Ralph E. Lawson
Baptist Health South Florida
Coral Gables, FL

Gilles B. Legault
Global Legal Affairs
Montreal, Quebec, Canada

Marie McDemmond
Pompano Beach, FL

Rodman N. Myers
Bloomfield, MI

Donald R. Proctor
Cisco Systems, Inc.
San Jose, CA

Steven T. Rosen, M.D., FACP
City of Hope
Duarte, CA

Frank O. Smith, MD
Medpace
Cincinnati, OH

Kathryn C. Vecellio
Palm Beach, FL

Louise G. Warner
Chagrin Falls, OH

Keith S. White
ParkerWhite Brand Interactive
Cardiff by the Sea, CA

Louis DeGennaro, PhD
President & CEO

Danielle Gee
Chief of Staff

Rosemarie Loffredo
Executive Vice President
Chief Financial &
Administrative Officer

George Omiros
Executive Vice President
Chief Campaign &
Field Development Officer

Mark Roithmayr
Executive Vice President
Chief Development Officer

THE LEUKEMIA & LYMPHOMA SOCIETY OF CANADA

Shelagh Tippet-Fagyas
President
Canadian Operations

BOARD OF DIRECTORS

James A. Beck
Hefren-Tillotson, Inc.
Butler, PA

William G. Behnke
The Behnke Group
San Antonio, TX

EXECUTIVE LEADERSHIP

OFFICES

Alabama

100 Chase Park South•Suite 220
Birmingham, AL 35244
205.989.0098

Alaska

See *Washington*

Arizona

3877 North 7th Street•Suite 300
Phoenix, AZ 85014
602.567.7600

Arkansas

See *Missouri*

California

340 West Fallbrook Avenue
Suite 101
Fresno, CA 93711
559.435.1482

6033 West Century Boulevard
Suite 300
Los Angeles, CA 90045
310.342.5800

765 The City Drive South
Suite 450
Orange, CA 92868
714.481.5600

7750 College Town Drive•Suite 210
Sacramento, CA 95826
916.929.4720

9150 Chesapeake Drive•Suite 100
San Diego, CA 92123
858.277.1800

221 Main Street•Suite 1650
San Francisco, CA 94105
415.625.1100

675 North First Street•Suite 1100
San Jose, CA 95112-5156
408.490.2666

2455 Bennett Valley Road,
Suite B204
Santa Rosa, CA 95404
707.544.4350

Colorado

720 South Colorado Boulevard
Suite 500-S
Denver, CO 80246
720.440.8620

Connecticut

372 Danbury Road•Suite 200
Wilton, CT 06897
203.665.1400

Delaware

100 West 10th Street•Suite 209
Wilmington, DE 19801
302.661.7300

Florida

200 South Park Road
Suite 140
Hollywood, FL 33012
954.744.5300

3319 Maguire Boulevard•Suite 101
Orlando, FL 32803
407.898.0733

7077 Bonneval Road
Suite 103
Jacksonville, FL 32216
904.332.6414

3230 Commerce Place•Suite B
West Palm Beach, FL 33407
561.616.8682

3507 East Frontage Road•Suite 300
Tampa, FL 33607
813.963.6461

Georgia

3715 Northside Parkway
Building 400•Suite 300
Atlanta, GA 30327
404.720.7900

340 Eisenhower Drive•Suite 220
Savannah, GA 31406

Hawaii

P.O. Box 29518
Honolulu, HI 96820
800.215.1098

Idaho

2404 West Bank Drive•Suite 103
Boise, ID 83705
208.658.6662

Illinois

651 West Washington Boulevard
Suite 400
Chicago, IL 60661
312.651.7350

Indiana

9075 N. Meridian St.
Suite 150
Indianapolis, IN 46260
317.860.3840

Iowa

2700 Westown Pkwy. •Suite 260
West Des Moines, IA 50266
515.270.6169

St. Luke's Hospital
1026 A Avenue NE, RC107
Cedar Rapids, IA 52406-3026
319.362.1476

Kansas

6811 Shawnee Mission Parkway
Cloverleaf Building #1•Suite 202
Shawnee Mission, KS 66202-4001
913.262.1515
300 North Main•Suite 300
Wichita, KS 67202
316.266.4050

Kentucky

301 East Main Street•Suite 100
Louisville, KY 40202-1077
502.584.8490

836 Euclid Ave., #317
Lexington, KY 40502
859.226.0764

Louisiana

3636 South 1-10 Service Road
Suite 304
Metairie, LA 70001
504.837.0945

Maine

See *Massachusetts*

Maryland

100 Painters Mill Road•Suite 800
Owings Mills, MD 21117
443.471.1600

Massachusetts

9 Erie Drive
Natick, MA 01760
508.810.1300

Michigan

1471 East Twelve Mile Road
Madison Heights, MI 48071
248.581.3900

Minnesota

1711 Broadway Street NE
Minneapolis, MN 55413
612.259.4600

Missouri

1972 Innerbelt Business Center Dr.
St. Louis, MO 63114
314.590.2230

6811 Shawnee Mission Parkway
Cloverleaf Building #1•Suite 202
Shawnee Mission, KS 66202-4001
913.262.1515

Montana

See *Oregon*

Nebraska

12100 W. Center Road
Bldg. 1•Suite 202
Omaha, NE 68144
402.344.2242

Nevada

6280 South Valley View Boulevard
Suite 342
Las Vegas, NV 89118
702.436.4220

New Hampshire

See *Massachusetts*

New Jersey

14 Commerce Drive•Suite 301
Cranford, NJ 07016
908.956.6600

New Mexico

4600-A Montgomery Boulevard NE
Suite 201
Albuquerque, NM 87109
505.872.0141

New York

5 Computer Drive West•Suite 100
Albany, NY 12205
518.438.3583
4043 Maple Road•Suite 105
Amherst, NY 14226
716.834.2578

1324 Motor Parkway•Suite 102
Hauppauge, NY 11749
631.370.7530

61 Broadway•Suite 400
New York, NY 10006
212.376.7100

1311 Mamaroneck Avenue•Suite 130
White Plains, NY 10605
914.949.0084

North Carolina

401 Harrison Oaks Boulevard
Suite 200
Cary, NC 27513
919.367.4100

4530 Park Road •Suite 240
Charlotte, NC 28209
704.705.1850

North Dakota

See *Minnesota*

Ohio

4370 Glendale-Milford Rd.
Cincinnati, OH 45242
513.698.2828
5700 Brecksville Road•3rd Floor
Independence, OH 44131
216.264.5680

2215 Citygate Drive•Suite A
Columbus, OH 43219
614.476.7194

Oklahoma

500 North Broadway•Suite 250
Oklahoma City, OK 73102
405.943.8888

Oregon

9320 SW Barbur Boulevard
Suite 350
Portland, OR 97219
503.245.9866

Pennsylvania

555 North Lane•Suite 5010
Conshohocken, PA 19428
610.238.0360
2405 Park Drive•Suite 100
Harrisburg, PA 17110
717.652.6520
333 East Carson Street•Suite 441
Pittsburgh, PA 15219
412.395.2873

Rhode Island

2348 Post Road•Suite 202
Warwick, RI 02886
401.943.8888

South Carolina

107 Westpark Boulevard•Suite 150
Columbia, SC 29210
803.731.4060

941 Houston Northcutt Blvd.
Suite 203
Mt. Pleasant, SC 29464
843.881.8176

1990 Augusta Street
Suite 600
Greenville, SC 29605
864.370.2402

South Dakota

See *Minnesota*

Tennessee

404 BNA Drive•Suite 102
Nashville, TN 37217
615.331.2980

Texas

8111 LBJ Freeway•Suite 425
Dallas, TX 75251
972.996.5900

1300 Summit Avenue•Suite 110
Ft. Worth, TX 76102
817.288.2630

5433 Westheimer Road•Suite 300
Houston, TX 77056
713.840.0483

1218 Arion Parkway•Suite 102
San Antonio, TX 78216
210.998.5400

8001 Centre Park Dr. •Suite 150
Austin, TX 78754
512.491.6610

4311 North 10th Street•Suite D
McAllen, TX 78504
956.664.1629

Utah

5296 Commerce Drive•Suite 101
Murray, UT 84107
801.281.6618

Vermont

See *Albany, NY*

Virginia

5540 Falmouth Street•Suite 101
Richmond, VA 23230
804.673.5690

6350 Center Dr.
Suite 216
Norfolk, VA 23502
757.459.4670

Washington

123 NW 36th Street•Suite 100
Seattle, WA 98107
206.628.0777

Washington D.C.

3601 Eisenhower Ave. •Suite 450
Alexandria, VA 22304
703.399.2900

West Virginia

See *Pittsburgh, PA*

Wisconsin

200 South Executive Drive•Suite 203
Brookfield, WI 53005
262.790.4701

Wyoming

See *Colorado*

PUERTO RICO

Comercial 18
800 Roberto H. Todd Avenue
Suite 206
San Juan, PR 00907
787.725.2200

CANADA

Canada Corporate—Ontario
2 Lansing Square•Suite 804
Toronto, ON M2J 4P8
416.661.9541
Canada Corporate - Quebec
740 St. Maurice Street•Suite 602
Montreal, QC H3C 1L5
514.395.5275
Atlantic Canada Region
1660 Hollis Street•HS2
Halifax, NS B3J 1V7
902.422.5999
BC/Yukon Region
1682 West 7th Avenue•Suite 310
Vancouver, BC V6J 4S6
604.733.2873
Prairies Region
2020 10th Street NW
Calgary, AB T2M 3M2
403.263.5300
Région de Québec
705-1255 University Street
Montréal, QC H3B 3W1
514.875.1000

1311 Mamaroneck Ave.
Suite 310
White Plains, NY 10605
914.949.5213
www.lls.org

LLS CELEBRATES
65 YEARS SINCE
ITS INCEPTION
IN 1949.



**JOIN US. RAISE YOUR
HAND. DECLARE YOUR
SUPPORT. TOGETHER
WE CAN END CANCER.
DONATE TODAY:
LLS.ORG/DONATE**

MISSION: CURE LEUKEMIA,
LYMPHOMA, HODGKIN'S
DISEASE AND MYELOMA,
AND IMPROVE THE QUALITY
OF LIFE OF PATIENTS AND
THEIR FAMILIES.



**someday
is today**  **LEUKEMIA &
LYMPHOMA
SOCIETY®**
fighting blood cancers